



KSSSS 2026

The 43rd International Congress of
Korean Society of Spine Surgery

May 20 (Wed) - 22 (Fri), 2026

Lotte Hotel Seoul (Sogong-dong), Seoul, Korea

Program Book



근골격계질환

Better option Better relief

신바로® / 펠루비® / 아티폴® / 보니센원스® / 테로사®



KSSSS 2026

C O N T E N T S

Welcome Message	02
Organizing Committee	03
Program at a Glance	12
Scientific Program	13
Venue Information	42
Booth Layout	43
Conference Information	44
Sponsors	49



Welcome Message

Dear Colleagues and Friends,

It is my great pleasure and honor to welcome you to the 43rd International Congress of Korean Society of Spine Surgery (KSSS 2026), which will be held in Seoul, Korea, from May 20 to 22, 2026.

KSSS 2026 will offer participants a dynamic and advanced scientific program, featuring cutting-edge technologies and the latest advances in spine surgery, while also offering valuable opportunities to strengthen global connections and friendships.

Building upon the long-standing tradition and academic excellence of KSSS, this congress aims to foster international collaboration and inspire innovations in spinal care. Participants will have the chance to share new knowledge, exchange ideas, and engage in in-depth discussions through podium and poster presentations. In addition, an Instructional Course Lecture (ICL) will be offered as a pre-congress program to further enrich the academic experience.

Beyond the scientific sessions, we warmly invite you to experience the unique charm and hospitality of Seoul, a dynamic city where tradition meets innovation.

We look forward to welcoming you to KSSS 2026 and to sharing an unforgettable and inspiring experience together in Seoul, Korea.

Yours sincerely,

김경수

Kyung-Soo Suk, MD, PhD

President, Korean Society of Spine Surgery



Organizing Committee

President	Kyung-Soo Suk	
President-elect	Seok Woo Kim	
Honorary President	Se-Il Suk	
Secretary General	Ho-Joong Kim	
Audit	Young Bae Kim, Chang Hwa Hong	
Vice-secretary	Se-Jun Park	
Advisory (Past presidents)	Kwang-Yoon Seo, Byung-Hoon An, Chung-Bin Chu, Kwang-Hoe Kim, Se-Il Suk, Byung-Moon Park, Myung-Sang Moon, Seung-Ho Yoon, Key-Yong Kim, Nam-Hyun Kim, Hong-Tae Kim, Jin-Man Wang, Young-Gu Lee, Ki-Su Kim, Young-Khee Jung, Jae-Rim Cho, Seung-Rim Park, Yung-Tae Kim, Byung Chul Park, June Kyu Lee, Jae Yoon Chung, Heui-Jeon Park, Myun-Whan Ahn, Kee-Yong Ha, Choon-Ki Lee, Jae-Won You, Byung-Joon Shin, Choon Sung Lee, Hwan Mo Lee, Chong-Suh Lee, Ki-Tack Kim, Kyu-Yeol Lee, Whoan Jeang Kim, Chang-Hoon Jeon, Dong-Jun Kim, Hak-Sun Kim, Kyu-Jung Cho, Bong-Soon Chang, Yong Soo Choi, Tae-Kyun Kim, Jong-Beom Park	
Board of Directors	Chang-Nam Kang, Sang Bum Kim, Seok Woo Kim, Yong-Chan Kim, Jin-Hwan Kim, Tae-Kyun Kim, Woo Dong Nam, Woo-Kie Min, Yung Park, Jong-Beom Park, Kyung-Soo Suk, Dong-Ho Lee, Jung Sub Lee, Jae Chul Lee, Jae Hyup Lee, Soo Taek Lim, Jung-Pil Heo	
Program & Scientific Committee	Chairman	Jin Sup Yeom
	Director	Ji-Won Kwon
	2nd year	Ji-Won Kwon (Director), Sung-Soo Kim, Young-Yul Kim, Woo-Kie Min, Se-Jun Park, Dong Ki Ahn, Gun Woo Lee, Dong-Ho Lee, Jae-Hyup Lee, Dong-Gune Chang, Nam-Su Chung, Jae-Young Hong
1st year	Kyung-Chung Kang, Jong-Hyun Ko, Namhoo Kim, Sung-Kyu Kim, Young-Woo Kim, Chang Su Kim, Moon Soo Park, Si-Young Park, Jin-Sung Park, Hyun-Jin Park, Jaewan Soh, Jae Jun Yang, Jin Sup Yeom, Suk-Joong Lee, Ho-Jin Lee, Sam Yeol Chang, Hae-Dong Jang, Dae-Woong Ham	
Editorial Committee of Journal of Korean Society of Spine Surgery	Chairman	Si-Young Park
	Director	Jae-Hyuk Yang
	3rd year	Ye-Soo Park, Hyoung-Yeon Seo, Kwang-Sup Song, Dong-Eun Shin, Jae-Hyuk Yang (Director), Nam-su Chung, Byung-Wan Choi
2nd year	Sang-Bong Ko, Sang-Bum Kim, Young-Hoon Kim, Hyoung-Min Kim, Woo-Dong Nam, Woo-Kie Min, Jae-Jun Yang, Bong-Soon Chang	
1st year	Tae-Kyun Kim, Si-Young Park, Hyun-Jin Park, Chang-Hwa Hong, Chang-Ju Hwang	

<p>Editorial Committee of Asian Spine Journal</p>	<p>Chairman Hak-Sun Kim Director Jae Hwan Cho</p> <p>3rd year Ji-Won Kwon, Hak-Sun Kim, Se-Jun Park, Sehan Park, Jin Sung Park</p> <p>2nd year Sung-Soo Kim, Kun-Bo Park, Jae-Chul Lee, Jae Hwan Cho (Director)</p> <p>1st year Sang Il Kim, Sung-Kyu Kim, Ho-Joong Kim, Sang-Min Park, Hyung-Youl Park, Gun Woo Lee, Byung Ho Lee, Dong-Gune Chang, Sam Yeol Chang, Hae-Dong Jang, Sung Hoon Choi</p>
<p>Insurance Committee</p>	<p>Chairman Chang Hwa Hong Director Han-Dong Lee</p> <p>3rd year Min-Seok Kim, Jung-Hoon Kim, Jin-Hwan Kim, Ki Se Nam, Si Young Park, Hun Kyu Shin, Dong Ki Ahn, Jeong Hyun Yoo, Byung Ho Lee, Jun-Seok Lee, Hae-Dong Jang, Sung Hoon Choi, Yong-Gi Choi</p> <p>2nd year Kyu Bok Kang, Chang-Nam Kang, Yong-Chan Kim, Hyun-Jin Park, Seung-Pyo Suh, Seung-Deok Sun, Jae Jun Yang, Han-Dong Lee (Director), Ho-Jin Lee, Taek Soo Jeon</p> <p>1st year Dong-Ho Kang, Nam-Hoo Kim, Kun Young Park, Jiwon Park, Joonoh Seo, In-Seok Son, Minjoon Cho</p>
<p>Bylaws Committee</p>	<p>Chairman Kyu-Jung Cho Secretary Ho-Joong Kim</p> <p>Seok Woo Kim, Ho-Joong Kim (Secretary), Si Young Park, Kyung-Soo Suk (President), Jae Chul Lee, Kyu-Jung Cho</p>
<p>Website Committee</p>	<p>Chairman Kwang-Sup Song Director Jaewan Soh</p> <p>2nd year Young-Woo Kim, Yong-Chan Kim, Kun-Woo Park, Kun Young Park, Jaewan Soh (Director), Kwang-Sup Song, Joong hyun Ahn, Jae-Young Hong</p> <p>1st year Young Bae Kim, Hyoung Min Kim, Sang-Min Park, Kee-Won Rhyu, Jae Chul Lee, Sam Yeol Chang, Sung Hoon Choi, Chang Ju Hwang</p>
<p>Public Relations Committee</p>	<p>Chairman Kyung-Chung Kang Director Sub-Ri Park</p> <p>2nd year Jong-Hyun Ko, Dong-Ho Kang, Tae-Hoon Kang, Sub-Ri Park (Director), Ji-Won Park, Hyun-Jin Park, Hee Jung Son, Jae-Won Shin, Ki-Young Lee, Jun-Young Choi, Dae-Woong Ham</p> <p>1st year Kyung-Chung Kang, Kyoung-Hwan Kim, Han-Dong Lee, Hyung-Rae Lee</p>
<p>Board of Education</p>	<p>Chairman Jae Hyup Lee Director Hyung-Youl Park</p> <p>Jong-Hyun Ko, Ki Youn Kwon, Sung-Kyu Kim, Yong-Chan Kim, Ho-Joong Kim, Woo-Kie Min, Se-Jun Park, Ji-Won Park, Hyung-Youl Park (Director), Byung Ho Lee, Jae Hyup Lee, Han-Dong Lee, Ho-Jin Lee, Nam-Su Chung, Chang Ju Hwang</p>
<p>Finance Committee</p>	<p>Chairman Kyung-Soo Suk Secretary Ho-Joong Kim</p> <p>Seok Woo Kim, Ho-Joong Kim (Secretary), Whoan-Jeang Kim, Se-Jun Park, Jong-Beom Park, Kyung-Soo Suk (President), Jae Jun Yang, Kee-Won Rhyu, Young-Khee Chung</p>

CGBIO,

From Precision to Predictable Outcomes.

CGBIO
CELL & GROWTH FACTOR
BIOTECHNOLOGY

Refine
Every **Detail.**
Elevate
Every **Surgery.**



PRECISION. PASSION. PERFECT OUTCOMES.

Plan & Guide : CUVIS-Spine Navigation & Robot system

Navigate with Confidence.
Real-time 3D guidance for safer, more precise procedures.



See & Access : Solendos Endoscope system

Direct Vision. Targeted Access.
Endoscopic clarity to see the pathology and reach it — minimally invasive.



Expand & Stabilize : EXCENDER Expandable Cage

Restore Height. Rebuild Stability.
In-situ expandable technology for optimal disc space restoration.



환자마다 출발점이 다릅니다.

MEET HER THERE

골절 위험이 높은 골다공증 환자의 치료 여정에
이베니티®, **프로리아®**가 언제나 함께합니다.



최근 골절을 동반하거나 골밀도가 매우 낮은
초고위험 골다공증 환자는 골 형성을 위해
이베니티®로 치료 시작해 주세요!¹⁻³

골밀도가 낮거나 골절 위험요소가 있는
고위험군 골다공증 환자는 골 흡수를 막기 위해
프로리아®로 치료 시작해 주세요!¹⁻³



References 1. Camacho PM, et al. *Endocr Pract.* 2020;26(Suppl 1):1-46. 2. Shoback D, et al. *J Clin Endocrinol Metab.* 2020;105(3):587-594. 3. Eastell R, et al. *J Clin Endocrinol Metab.* 2019;104(5):1595-1622.

Product Information

처방하시기 전 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(<https://nedrug.mfds.go.kr>)을 통해 상세 제품정보를 참조하시기 바랍니다.



암젠코리아유한회사
서울특별시 중구 을지로5길 19, 20층 Tel. 02-3434-4899




중 근 당

공동판매원 중근당주식회사
서울특별시 서대문구 중정로 8 (충정로 3가) TEL 02-2194-0300 FAX 02-2194-0369
소비자상담실 : 080-6776-080 (수신자부담) 제품상세정보 : www.ckdpharm.com 참조

PYXIS™

3D Printing TI OLIFII Cage



Key feature & Benefits

- Irregular Porous Structure : Increased osteoblast cell proliferation and osteogenic factor secretion
- Minimized Sharp Edge : Minimizing damage and easier insertion
- Optimized Frame Thickness : Restore disc space and stability
- 3D Printing Titanium Cage : Increase bone growth and minimized elastic modulus of Ti6Av4V

불이 켜졌습니다.
걸어야 할 시간입니다.

오파몬(Limaprost) 은,
요부척추관협착증 환자의
보행거리를 개선합니다.

ONT-231.038

Limaprost alfadex
Opalmon[®] Tab.
Lumbar Spinal Stenosis

Stay Strong with Stoboclo™

Strong Bones, Stronger You



스토보클로프립리드시린지(데노수맵) 제품정보

[효능·효과] 1. 폐경 후 여성 골다공증 환자의 치료 2. 남성 골다공증 환자의 골밀도 증가를 위한 치료 3. 글루코코르티코이드 유발성 골다공증의 치료 4. 안드로겐 차단요법을 받고 있는 비전이성 전립선암 환자의 골 소실 치료 5. 아로마타제 억제제 보조요법을 받고 있는 여성 유방암 환자의 골 소실 치료 **[용법·용량]** 이 약은 보건의료 전문가에 의해 투여되어야 한다. 이 약 1 시린지(데노수맵 60 mg)를 매 6개월마다 상완, 허벅지 위쪽 또는 복부에 피하 주사한다. 모든 환자는 칼슘 1000 mg과 비타민D 400 IU 이상을 매일 복용해야 한다. 정기 투여일에 이 약을 투여하지 못했을 경우, 가능한 빨리 투여한다. 그 후, 마지막 투여일자로부터 매 6개월마다 투여한다.



스토보클로프립리드시린지(데노수맵) 제품정보

자세한 제품 정보 확인을 위해 QR code로 연결된 제품 설명서를 참고하여 주시기 바랍니다.

오직 환자를 위한 오리지널 프레가발린, 리리카

Original LYRICA의 가치

ONLY*



신경병증성 통증 치료제 국내 처방량 부분 판매 1위¹

(UBIST D1 Sales 2022년 2월부터 2024년 1월까지 기준)



투여 1주차부터 나타난 위약 대비 유의한 통증감소 효과²

(리리카를 투여 받은 당뇨병성 말초신경병증성 통증 환자 기준)



다양한 국내/외 가이드라인³에서

신경병증성 통증 1차 치료제 중 하나로 권고된 리리카³⁻¹²



안전성 프로파일 확인¹³

* ONLY는 Original Lyrica의 약어입니다. * 단, 리리카® CR 서방정의 경우 말초 신경병증성 통증의 치료에 한합니다.¹⁴

¹Abbreviations: AAN, American Academy of Neurology; ADA, American Diabetes Association; CPS, Canadian Pain Society; EFNS, European Federation of Neurological Societies; ESMO, European Society for Medical Oncology; IASP, International Association for the Study of Pain; JSPC, Japan Society of Pain Clinicians; KSSS, Korean Society of Spine Surgery; NICE, National Institute for Health and Care Excellence; KDA, Korean Diabetes Association.

References 1. UBIST D1 Sales (2022.02 ~2024.01) 2. R. Freeman, et al. Diabetes Care. 2008. Jul;31(7):1448-54. 3. 2010 EFNS Attal N, et al. 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113-e88 4. 2011 KSSS: KJ Chung, et al. J Korean Soc Spine Surg 2011 Dec;18(4):246-253. 5. 2015 IASP: Finnerup NB, et al. Lancet Neurol. 2015 Feb;14(2):162-73. 6. 2018 JSPC: Sumitani M, et al. Journal of Anesthesia 2018;32:463-478. 7. 2017 CPS: D Moulin, et al. Pain Res Manag. Nov-Dec 2014;19(6):328-35. 8. 2018 ESMO: M Fallon, et al. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166-iv191. 9. 2020 NICE: Brill V, et al. Neurology. 2011 May 17;76(20):1758-1765. 10. 2023 ADA: ElSayed NA, et al. Diabetes Care 2023;46(Suppl. 1):S203-S215. 11. 2021 AAN: Price R, et al. Neurology. 2022 Jan 4;98(1):31-43. 2021 12. 2023 당뇨병성 말초신경병증 치료제 13. Freynhagen R, et al. Pain Practice. 2015;15(1):47-57. 14. 리리카® CR 서방정 제품설명서. 최종변경하기림. 2025.3.18





The Korean Society of Spine Surgery



SUBSCRIBE
To Keep Updated



대한척추외과학회 | 러닝하면 무릎에 독이 될까? 5편
대한척추외과학회[적유브] 및 서울대 정형외과 척추...
조회수 122회 • 4개월 전



대한척추외과학회 | 10km 뛰고 엑스레이 찍어봤습니다 4편
대한척추외과학회[적유브] 및 서울대 정형외과 척추...
조회수 233회 • 4개월 전



대한척추외과학회 | 골다공증 환자, 러닝하면 생기는일 3편
대한척추외과학회[적유브] 및 서울대 정형외과 척추...
조회수 138회 • 4개월 전



대한척추외과학회 | 허리 협착증 환자 러닝해도 될까요? 2편
대한척추외과학회[적유브] 및 서울대 정형외과 척추...
조회수 738회 • 4개월 전



대한척추외과학회 | 허리디스크 환자 러닝해도 되나요? 1편
대한척추외과학회[적유브] 및 서울대 정형외과 척추...
조회수 1.1천회 • 4개월 전



2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 144회 • 5개월 전



2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 158회 • 5개월 전




2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 118회 • 5개월 전



2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 93회 • 5개월 전



2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 69회 • 5개월 전



2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 90회 • 5개월 전



2025년 제 42회 대한척추외과학회 국제학술대회 video exhibition
조회수 149회 • 5개월 전

Program at a Glance

May 20 (Wed)

Time	Sapphire Ballroom	
13:00 - 17:00	KSSS 2026 Instructional Course Lecture (ICL) (Sapphire Ballroom 3F)	
17:00 - 17:10	Group Photo (Sapphire Ballroom 3F)	
17:10 - 18:00	Cocktail Reception (Sapphire Ballroom Foyer 3F)	Presidential Roundtable Meeting (Pine Room 3F)
18:00 - 20:00	Welcome Reception (Sapphire Ballroom 3F)	

May 21 (Thu)

Time	Crystal Ballroom A	Crystal Ballroom B
07:10 - 07:50	Breakfast Symposium I	Breakfast Symposium II
07:50 - 08:00	Opening Remarks (Crystal Ballroom A)	
08:00 - 08:30	MISS (1)	Cervical (1)
08:30 - 09:00	MISS (2)	Cervical (2)
09:00 - 09:30	MISS (3)	Cervical (3)
09:30 - 09:50	Invited Lecture I	Invited Lecture II
09:50 - 10:10	Coffee Break	
10:10 - 10:50	Plenary Lecture I (Crystal Ballroom A)	
10:50 - 11:50	Asian Spine Society Session I	Asian Spine Society Session II
11:50 - 12:30	Luncheon Symposium I	Luncheon Symposium II
12:30 - 13:00	KSSS General Assembly (Crystal Ballroom A)	
13:00 - 14:00	Symposium I	Symposium II
14:00 - 14:20	Invited Lecture III	Invited Lecture IV
14:20 - 14:40	Coffee Break	
14:40 - 15:10	MISS (4)	Cervical (4)
15:10 - 15:40	Lumbar (1)	Deformity (1)
15:40 - 16:10	Lumbar (2)	Deformity (2)
16:10 - 16:50	KSSS Research Award (Crystal Ballroom A)	
16:50 - 17:00	Group Photo (Crystal Ballroom A)	
17:00 - 18:00	Cocktail Reception (Exhibition Hall, 2F)	
18:00 - 20:00	Gala Dinner (Crystal Ballroom)	

May 22 (Fri)

Time	Crystal Ballroom A	Crystal Ballroom B
07:10 - 08:00	Breakfast Symposium III	Breakfast Symposium IV
08:00 - 08:30	Best Paper Candidates Presentation I (Domestic)	Deformity (3)
08:30 - 09:00	Best Paper Candidates Presentation II (Domestic)	Deformity (4)
09:00 - 09:30	Best Paper Candidates Presentation III (Domestic)	Basic Research (1)
09:30 - 10:00	Best Paper Candidates Presentation IV (International)	Basic Research (2)
10:00 - 10:20	Coffee Break	
10:20 - 10:50	Best Paper Candidates Presentation V (International)	Tumor
10:50 - 11:20	Best Paper Candidates Presentation VI (International)	Trauma
11:20 - 11:40	Invited Lecture V	Invited Lecture VI
11:40 - 12:20	Plenary Lecture II (Crystal Ballroom A)	
12:20 - 13:20	Luncheon Symposium III	Luncheon Symposium IV
13:20 - 14:20	Symposium III	Symposium IV
14:20 - 14:40	Invited Lecture VII	Invited Lecture VIII
14:40 - 15:00	Coffee Break	
15:00 - 15:30	Lumbar (3)	Infection
15:30 - 16:00	Lumbar (4)	Infection & Miscellaneous
16:00 - 16:40	Traveling Fellowship & Asian Spine Society Visiting Reports (Crystal Ballroom A)	
16:40 - 17:00	Best Paper Awards (Crystal Ballroom A)	
17:00 - 17:10	Closing Remarks (Crystal Ballroom A)	
17:10 - 17:20	Farewell and Inauguration Ceremony for the President of KSSS (Crystal Ballroom A)	

Scientific Program

May 20 (Wed)

Sapphire Ballroom

13:00-13:05	Opening Remarks by the President of Korean Society of Spine Surgery (KSSS)	Kyung-Soo Suk (<i>Korea</i>)
13:05-14:15	Instructional Course Lecture: Cervical Spine	Jong-Beom Park (<i>Korea</i>) Ronald P. Tangente (<i>Philippines</i>)
13:05-13:15	S001 Upper Cervical Deformities	Sang Hun Lee (<i>USA</i>)
13:15-13:25	S002 Treatment Strategy for Atlantoaxial Rotatory Fixation (AARF)	Ken Ishii (<i>Japan</i>)
13:25-13:35	S003 Surgical Management of Retrodental Mass Causing Severe Myelopathy	Jin Sup Yeom (<i>Korea</i>)
13:35-13:45	S004 Surgical Strategies for the Management of K-line (-) OPLL Myelopathy	Dong-Ho Lee (<i>Korea</i>)
13:45-13:55	S005 Motion Preserving Surgeries for Cervical Radiculopathy	Jae Jun Yang (<i>Korea</i>)
13:55-14:15	Discussion	
14:15-14:30	Coffee Break	
14:30-15:40	Instructional Course Lecture: MIS	Seok Woo Kim (<i>Korea</i>) Dipak Shrestha (<i>Nepal</i>)
14:30-14:40	S006 Surgical Considerations and Long-Term Outcomes of MIS TLIF	Jae Chul Lee (<i>Korea</i>)
14:40-14:50	S007 Experience with Indirect Decompression, Single Position Surgery and Emerging Technologies for Lateral Lumbar Interbody Fusion	Jason Pui Yin Cheung (<i>Hong Kong</i>)
14:50-15:00	S008 How to Avoid and Manage the Complications of Endoscopic Decompression and Discectomy	Si Young Park (<i>Korea</i>)
15:00-15:10	S009 Long-Term Results of Percutaneous Endoscopic Debridement and Drainage (PEDD) for Lumbar Spine Infectious Spondylodiscitis	Tsai-Sheng Fu (<i>Taiwan</i>)
15:10-15:20	S010 Current Evidence and Limitation of Biportal Endoscopic Transforaminal Lumbar Interbody Fusion	Hyun-Jin Park (<i>Korea</i>)
15:20-15:40	Discussion	

May 20 (Wed)

Sapphire Ballroom

15:40-17:00	Instructional Course Lecture: Deformity	Kyu-Jung Cho (<i>Korea</i>) Chun-Man Ma (<i>Hong Kong</i>)
15:40-15:50	S011 Clinical Significance of Sacral Slanting in Patients with Adolescent Idiopathic Scoliosis	Chang Ju Hwang (<i>Korea</i>)
15:50-16:00	S012 Challenges in Surgical Correction and Balancing of Lenke 5C Curves	Chee-Kidd Chiu (<i>Malaysia</i>)
16:00-16:10	S013 Analysis of Apex and Its Importance in Severe Spinal Deformity Correction	Sudhir Kumar Srivastava (<i>India</i>)
16:10-16:20	S014 Hip-Spine Syndrome	Yat-Wa Wong (<i>Hong Kong</i>)
16:20-16:30	S015 Adult Lumbar-TL Spinal Deformity: When Is It Appropriate to Stop Short of Sacrum/Pelvis	Khaled M. Kebaish (<i>USA</i>)
16:30-16:40	S016 Automated Computed Tomography-Based Body Composition Analysis and Utility in Risk Stratification for Adult Spinal Deformity Correction – Implications for Proximal Junctional Kyphosis and Complications	John H. Shin (<i>USA</i>)
16:40-17:00	Discussion	
17:00-17:10	Closing & Group Photo	
17:10-18:00	Cocktail Reception (Sapphire Ballroom Foyer 3F) / President Roundtable Meeting (Pine Room 3F)	
18:00-20:00	Welcome Reception (Sapphire Ballroom 3F)	

May 21 (Thu)

Crystal A

07:10 - 07:50	Breakfast Symposium I	Hyun-Jin Park (Korea)
07:10 - 07:25	P1 [Sponsored by SK chemicals]  Medical Treatment of Back Pain – NSAIDS & Muscle Relaxants	Jiwon Park (Korea)
07:25 - 07:40	P1 [Sponsored by Hanmi Pharmaceutical]  Efficacy & Safety from a Global Phase 3 Trial Including Korean: Obodence (Denosumab biosimilar)	Jaewon Shin (Korea)
07:40 - 07:50	Break	
07:50 - 08:00	Opening Remarks (Crystal Ballroom A)	Kyung-Soo Suk (President of KSSS)
08:00 - 08:30	MISS (1)	Hyoung-Yeon Seo (Korea) Jae-Young Hong (Korea)
08:00 - 08:04	P1 S017 Preoperative VBQ Score and Early Cage Subsidence After Endoscopic Lumbar Interbody Fusion: A Propensity Score–Matched Comparison with TLIF	Howard Chen (Taiwan)
08:04 - 08:08	P2 S018 Clinical and Radiologic Outcomes of Biportal Endoscopic vs Microscopic Decompression for Lumbar Spinal Stenosis with Low-Grade Spondylolisthesis: A Pooled Analysis of Randomized Controlled Trials	Seung-Yeon Jeong (Korea)
08:08 - 08:12	P1 S019 Efficacy and Safety of Various Graft Choices in OLIF	Wantanun Lorwatthanakitchai (Thailand)
08:12 - 08:16	P2 S020 Predictive Factors of MIS Decompression in Lumbar Spinal Stenosis with Degenerative Lumbar Scoliosis	Piya Chavalparit (Thailand)
08:16 - 08:20	P1 S021 Hidden Blood Loss in Full-Endoscopic Lumbar Decompression Compared with Biportal Endoscopic and Microscopic Decompression for Single-Segment Lumbar Stenosis	Sung Cheol Park (Korea)
08:20 - 08:30	Discussion	
08:30 - 09:00	MISS (2)	Chang-Nam Kang (Korea) Si-Young Park (Korea)
08:30 - 08:34	P1 S022 Infective Spondylodiscitis After Full Endoscopic Lumbar Discectomy - A Single Center Retrospective 10 Year Analysis	Phani Kiran Surapuraju (India)

08:34 - 08:38	P2	S023 Biportal Endoscopic Transforaminal Lumbar Interbody Fusion Using an Expandable Cage for Meyerding Grade II or Higher Isthmic Spondylolisthesis: A Comparative Study with the Conventional Open Technique	Sub-Ri Park <i>(Korea)</i>
08:38 - 08:42	P1	S024 Beyond the Microscope: Is Endoscopic Discectomy the Next Gold Standard for Lumbar Disc Herniation?	Borriwat Santipas <i>(Thailand)</i>
08:42 - 08:46	P2	S025 Novel Endoscopic-Assisted Triple Realignment Strategy for Single-Position OLIF: A New Paradigm for Sagittal Correction and Indirect Decompression	Dong-Ho Kang <i>(Korea)</i>
08:46 - 08:50	P1	S026 Intraoperative Changes in Modified Coronal Root Angle Following Biportal Endoscopic Lumbar Decompressive Foraminotomy for Lumbar Foraminal Disc Disease	Min-Seok Kang <i>(Korea)</i>
08:50 - 09:00		Discussion	
09:00 - 09:30		MISS (3)	Chung-Hwan Kim <i>(Korea)</i> Kwang-Sup Song <i>(Korea)</i>
09:00 - 09:04	P1	S027 Full-Endoscopic Rhizotomy for Degenerative Lumbar Facet Joint Syndrome: A Systematic Review and Meta-Analysis	Peem Sara <i>(Thailand)</i>
09:04 - 09:08	P2	S028 Is Biportal Endoscopic Decompression Truly Muscle-Sparing? A Quantitative Analysis Using 3-Class MRI Segmentation	Jiseon Ahn <i>(Korea)</i>
09:08 - 09:12	P1	S029 Minimally Invasive Spine Surgery for Thoracolumbar Fractures Using Standard Instruments: A Cost-Effective Two-Center Prospective Study	Anup Pokhrel <i>(Nepal)</i>
09:12 - 09:16	P2	S030 Factors Associated with Patient Satisfaction One Year After 1-2 Level Minimally Invasive Transforaminal Lumbar Interbody Fusion: The Role of Foraminal Height and Segmental Lordosis	Jeongwoon Han <i>(Korea)</i>
09:16 - 09:20	P1	S031 Learning Curve for Biportal Endoscopic Transforaminal Lumbar Interbody Fusion (BE-TLIF) in a Junior Endoscopic Spine Surgeon: A Phase-Specific Retrospective Analysis	Tae Hoon Kang <i>(Korea)</i>
09:20 - 09:30		Discussion	
09:30 - 09:50		Invited Lecture I	Seok Woo Kim <i>(Korea)</i>
09:30 - 09:45	P1	S032 Challenges in Thoracic OPLL Posterior Surgery: Our Two-Stage Strategy	Shiro Imagama <i>(Japan)</i>

May 21 (Thu)

Crystal A

09:45 - 09:50	Discussion	
09:50 - 10:10	Coffee Break	
10:10 - 10:50	Plenary Lecture I	Kyung-Soo Suk (Korea)
10:10 - 10:25	P1 S033 Management of Cervical Spine Deformity: Present and Future	Sang Hun Lee (USA)
10:25 - 10:40	P1 S034 Lessons from 'En Bloc' Resections of Spine Tumors	Sang Hun Lee (USA)
10:40 - 10:50	Discussion	
10:50 - 11:50	Asian Spine Society Session I	Jong-Beom Park (Korea)
10:50 - 11:02	P1 S035 Thoracic Ossification of the Ligamentum Flavum	Ronald P. Tangente (Philippines)
11:02 - 11:05	Discussion	
11:05 - 11:17	P1 S036 Minimally Invasive Thoracolumbar Fracture Reduction Techniques with Percutaneous Pedicle Screws	Chee-Kidd Chiu (Malaysia)
11:17 - 11:20	Discussion	
11:20 - 11:32	P1 S037 Current Concepts of Vertebral Body Tethering for Non-Fusion AIS Surgery	Jason Pui Yin Cheung (Hong Kong)
11:32 - 11:35	Discussion	
11:35 - 11:47	P1 S038 Spine Injuries of 2025 Earthquake in Myanmar	Thant Zin Naing (Myanmar)
11:47 - 11:50	Discussion	
11:50 - 12:30	Luncheon Symposium I	Yung Park (Korea)
11:50 - 12:05	[Sponsored by CGBIO] CGBIO <small>CELL & GROWTH FACTOR BIOTECHNOLOGY</small> P1 Robotic-Navigated Endoscopic Lumbar Fusion Using CUVIS-Spine: Initial Clinical Experience	Sub-Ri Park (Korea)
12:05 - 12:20	[Sponsored by Amgen & Chong Kun Dang] AMGEN x CKD Pharm P1 EVENITY in Vertebral Fracture Patients: Improving Bone Strength and Clinical Outcomes	Hyung-Youl Park (Korea)
12:20 - 12:30	Break	

12:30 - 13:00	KSSS General Assembly (Crystal Ballroom A)	
13:00 - 14:00	Symposium I MISS: From Theory to Practice in MIS Techniques	
13:00 - 13:30	Session 1: The Next Frontier of Minimally Invasive Spine Surgery Jae Chul Lee (Korea), Jae Wan Soh (Korea)	
13:00 - 13:07	P1	S039 Next-Generation Osteobiologics for MIS Fusion: rhBMP-2, ABM/P-15, Bioactive Glass and Whitlockite Tae Hoon Kang (Korea)
13:07 - 13:14	P2	S040 Advanced Implant Design Enabling Minimally Invasive Stability - 3D-Printed Porous Titanium Pedicle Screws and Cage Jihyun Ryu (Korea)
13:14 - 13:21	P1	S041 Artificial Intelligence and Robotics in MIS Planning and Execution Sang-Min Park (Korea)
13:21 - 13:30	Discussion	
13:30 - 14:00	Session 2: Endoscopic Spine Surgery in Practice: Key Techniques and Pitfalls Yung Park (Korea) Jae Hyup Lee (Korea)	
13:30 - 13:37	P1	S042 Tips and Pitfalls in Cervical Endoscopic Surgery (Key Techniques and Pitfalls) Jae-Heung Shin (Korea)
13:37 - 13:44	P2	S043 Biportal Endoscopic Surgery - Interlaminar Approach Dong-Yun Kim (Korea)
13:44 - 13:51	P1	S044 Biportal Endoscopic Surgery - Far Lateral Approach Hyun-Jin Park (Korea)
13:51 - 14:00	Discussion	
14:00 - 14:20	Invited Lecture III Jae Chul Lee (Korea)	
14:00 - 14:15	P1	S045 Management Trend of the Early Onset Scoliosis Yat-Wa Wong (Hong Kong)
14:15 - 14:20	Discussion	
14:20 - 14:40	Coffee Break	
14:40 - 15:10	MISS (4) Deuk Soo Jun (Korea) Eun Seok Son (Korea)	
14:40 - 14:44	P1	S046 Comparison of Transforaminal Endoscopic Lumbar Foraminotomy (TELF) in Patients with Degenerative Scoliosis and Patients with Normal Alignment Chay-You Ang (Singapore)

May 21 (Thu)

Crystal A

14:44 - 14:48	P2	S047 O-arm Navigation–Assisted Biportal Endoscopic Spine Surgery for Extremely Migrated Lumbar Disc Herniation: A Case Series	Hyunjun Park (Korea)
14:48 - 14:52	P1	S048 Safety and Utility of Ultrasonic Tools in Biportal Endoscopy	Babu J Naresh (India)
14:52 - 14:56	P2	S049 Feasibility of the Pedicle Medial Line and Inferior Vertebral Upper Endplate as Portal Landmarks for Uniportal Endoscopic Lumbar Laminectomy	Jaeryeong Park (Korea)
14:56 - 15:00	P1	S050 Wound-Related Outcomes Following Endoscopic Versus Microscopic Lumbar Discectomy: A Post Hoc Analysis of Two Randomized Controlled Trials	Seok-In Jang (Korea)
15:00 - 15:10		Discussion	
15:10 - 15:40		Lumbar (1)	Yong Chan Kim (Korea) Sung-Kyu Kim (Korea)
15:10 - 15:14	P1	S051 Risk Factors for Hidden Blood Loss After Oblique Lumbar Interbody Fusion	Emmanuel Mwesigye (Uganda)
15:14 - 15:18	P2	S052 3D Printed Pedicle Screw: Porosity Range for Bone-Like Porous Structures to Ensure Sufficient Structural Stability	Yujin Go (Korea)
15:18 - 15:22	P1	S053 Outcomes of Open TLIF vs. MISS TLIF (Hybrid) for the Treatment of Spondylolisthesis: A Comparative Study	Md Rahman (Bangladesh)
15:22 - 15:26	P2	S054 Impact of Listhesis on One-Year Vertebral Compression Progression in Elderly Patients Aged 70 Years or Older	Sang Ho Kim (Korea)
15:26 - 15:30	P1	S055 Comparison of Total and Hidden Blood Loss Between BE-TLIF and Tubular Based MIS-TLIF: A Hematocrit-Based Retrospective Study with Learning Curve Effects	Tae Hoon Kang (Korea)
15:30 - 15:40		Discussion	
15:40 - 16:10		Lumbar (2)	Chang-Hwa Hong (Korea) Kun Young Park (Korea)
15:40 - 15:44	P1	S056 What Is the Optimal Cage Size in OLIF Surgery	Peerapon Nantapong (Thailand)
15:44 - 15:48	P2	S057 Long-Term Comparison of Proximal and Distal Adjacent Segment Degeneration After Short Fusion in the Lower Lumbar Spine: A Minimum 5-Year MRI-Based Study	Tae-Soo Shin (Korea)

15:48 - 15:52	P1	S058 Clinical and Radiologic Outcomes of the Use of Interlaminar Device (Coflex®) Among Patients with Low-Grade Lumbar Spondylolisthesis: A Single Center Study	Mikhail Lew Ver <i>(Philippines)</i>
15:52 - 15:56	P2	S059 Feasibility of the Sandwich Graft Technique in OLIF: A Retrospective Comparative Cohort Study	Junghyun Oh <i>(Korea)</i>
15:56 - 16:00	P1	S060 Validation of the VIEW Score: A Novel Intraoperative Grading Scale for Visualization in Endoscopic Spine Surgery	Surachat Jaroenwareekul <i>(Thailand)</i>
16:00 - 16:10		Discussion	
16:10 - 16:50	KSSS Research Award (Crystal Ballroom A)		
16:10 - 16:26	Progress Updates: 2025 Research Award		
16:26 - 16:38	KSSS 2026 Dong-A Research Award		
16:26 - 16:33	Presentation		
16:33 - 16:38	Discussion		
16:38 - 16:50	KSSS 2026 Daewon Research Award		
16:38 - 16:45	Presentation		
16:45 - 16:50	Discussion		
16:50 - 17:00	Group Photo (Crystal Ballroom A)		
17:00 - 18:00	Cocktail Reception (Exhibition hall, 2F)		
18:00 - 20:00	Gala Dinner (Crystal Ballroom)		

May 21 (Thu)



Crystal B

07:10 - 07:50	Breakfast Symposium II	Sang-Min Park (Korea)
07:10 - 07:25	P3 [Sponsored by Baxter] Baxter Right Product for Right Clinical Outcomes in Spine Surgery	Namhoo Kim (Korea)
07:25 - 07:40	P3 [Sponsored by Dalim Medical] dalim medical Hemostatic Efficacy and Safety of CollaStat® in a Spinal Surgery	Hyung-Youl Park (Korea)
07:40 - 07:50	Break	
08:00 - 08:30	Cervical (1)	Dong Ho Lee (Korea) Jae Jun Yang (Korea)
08:00 - 08:04	P3 S061 Biomechanical Consequences of Implant Footprint Mismatch and Positioning in Cervical Disc Replacement	Ming-Kai Hsieh (Taiwan)
08:04 - 08:08	P4 S062 Biomechanical Effects of Plate Length and Screw Angulation in Anterior Cervical Discectomy and Fusion: A Finite Element Analysis	Joonoh Seo (Korea)
08:08 - 08:12	P3 S063 Early Experience with Cervical Disc Arthroplasty: Learning Curve, Technical Evolution, and Perioperative Outcomes	Hui-Shan Angela Lim (Singapore)
08:12 - 08:16	P4 S064 Spontaneous Atlantoaxial Facet Joint Autofusion After Posterior C1–2 Fusion	Jaenam Lee (Korea)
08:16 - 08:20	P3 S065 Differentiation of CSA (Cervical Spondylotic Amyotrophy) and ALS (Amyotrophic Lateral Sclerosis) Through Electromyography	Suk-Joong Lee (Korea)
08:20 - 08:30	Discussion	
08:30 - 09:00	Cervical (2)	Woo-Kie Min (Korea) Hyoungmin Kim (Korea)
08:30 - 08:34	P3 S066 "Ligamentous Instability" in Structurally Stable Cervical Spine: A Paradigm Shift in the Mechanism of Dynamic Compression in Degenerative Cervical Myelopathy	Babu J Naresh (India)
08:34 - 08:38	P4 S067 Long-Term Reoperation Risks After Cervical Artificial Disc Replacement (ADR) Versus ACDF: A Nationwide Cohort Study of Over 120,000 Patients from 2010 to 2023	Junghyun Oh (Korea)
08:38 - 08:42	P3 S068 Selecting the Distal Fusion Level in Multilevel Posterior Cervical Fusion: Impact of C7-T1 Junctional Mobility on Postoperative Malalignment	Jaewon Shin (Korea)

08:42 - 08:46	P4	S069 Does Laminoplasty Provide Better Outcome Compared to Anterior Cervical Discectomy and Fusion for Patients with Spinal Canal-Cord Mismatch?	Sehan Park <i>(Korea)</i>
08:46 - 08:50	P3	S070 Radiological and Clinical Importance of Lamina Hinge Fractures After Open-Door Cervical Laminoplasty: A Propensity Score-Matched Study	Gumin Jeong <i>(Korea)</i>
08:50 - 09:00		Discussion	
09:00 - 09:30		Cervical (3)	Young-Sang Lee <i>(Korea)</i> Kyung Chung Kang <i>(Korea)</i>
09:00 - 09:04	P3	S071 Outcomes of Selective Laminectomy for Cervical Myelopathy in Khanh Hoa General Hospital	Manh Hoang Tran <i>(Vietnam)</i>
09:04 - 09:08	P4	S072 Correlation Between Clinical Outcomes and Electromyography in Proximal Type CSA Who Underwent ACDF with Total Uncinectomy	Suk-Joong Lee <i>(Korea)</i>
09:08 - 09:12	P3	S073 Beyond the Cage: Autologous Sternal Bone Marrow Aspirate as a Potent Biological Determinant of Success in Anterior Cervical Discectomy and Fusion: A Propulsive Comparative Study With 2 Years Follow-Up	Swayam Prakash Dash <i>(India)</i>
09:12 - 09:16	P4	S074 Does Adding Uncovertebral Foraminotomy to Anterior Cervical Discectomy and Fusion Improve Patient Outcomes? A 5-Year Propensity Score-Matched Analysis of MCID and Mechanical Complications	Dae Whan Kim <i>(Korea)</i>
09:16 - 09:20	P3	S075 Hidden Cervical Myelopathy Presenting Predominantly with Gait Disturbance Despite Moderate Radiologic Compression: A Case Series	Seonggeun Chu <i>(Korea)</i>
09:20 - 09:30		Discussion	
09:30 - 09:50		Invited Lecture II	Jin Sup Yeom <i>(Korea)</i>
09:30 - 09:45	P3	S076 Dropped Head Syndrome: Current Advances in Diagnosis and Treatment	Ken Ishii <i>(Japan)</i>
09:45 - 09:50		Discussion	
09:50 - 10:10		Coffee Break	

May 21 (Thu)

Crystal B

10:50 - 11:50	Asian Spine Society Session II		Tae-Kyun Kim (Korea)
10:50 - 11:02	P3	S077 Spine Tuberculosis Surgery: Not Just an Easy Case (Combine Meta-Analysis)	Primadenny A. Airlangga (Indonesia)
11:02 - 11:05	Discussion		
11:05 - 11:17	P3	S078 High Grade Spondylolisthesis: What Are the Options Available?	Dipak Shrestha (Nepal)
11:17 - 11:20	Discussion		
11:20 - 11:32	P3	S079 Safe Surgery in Spinal Deformity	Shah Alam (Bangladesh)
11:32 - 11:35	Discussion		
11:35 - 11:47	P3	S080 Outcome Study of Anterior Debridement and Instrumentation in Subaxial Cervical Spinal Tuberculosis	Thein Aung Kyaw (Myanmar)
11:47 - 11:50	Discussion		
11:50 - 12:30	Luncheon Symposium II		Woo-Kie Min (Korea)
11:50 - 12:05	P3	[Sponsored by GS Medical]  New ACP	Jae Jun Yang (Korea)
12:05 - 12:20	P3	[Sponsored by Hanmi Pharmaceutical]  Hanmi Pharm. A New Paradigm for Multi-Pain Management: Naxozol® (Now Including LBP)	Hee Jung Son (Korea)
12:20 - 12:30	Break		
13:00 - 14:00	Symposium II Cervical: Comprehensive Management of Multilevel Cervical Foraminal Stenosis		Bo-Gun Suh (Korea) Han-Dong Lee (Korea)
13:00 - 13:12	P3	S081 The Diagnostic Challenge: Identifying Symptomatic Levels in Multilevel Cervical Foraminal Stenosis	Sang Yun Seok (Korea)
13:12 - 13:24	P4	S082 Posterior Cervical Foraminotomy: How to Get Enough Decompression and Reduce Complications	Hyung Rae Lee (Korea)
13:24 - 13:36	P3	S083 When Decompression Alone Is Not Enough: Practical Indications for Fusion	Jiwon Park (Korea)

13:36 - 13:48	P4	S084 Can Total Disc Replacement Still Serve as a Therapeutic Alternative for Multi-Level Cervical Foraminal Stenosis?	Byung-taek Kwon <i>(Korea)</i>
13:48 - 14:00		Discussion	
14:00 - 14:20		Invited Lecture IV	Dong-Ho Lee <i>(Korea)</i>
14:00 - 14:15	P3	S085 Medially Directed Lateral Mass Screw for Cervical Spine Fixation: Feasibility Study Using CT Scan and Preliminary Clinical Results	Chun-Man Ma <i>(Hong Kong)</i>
14:15 - 14:20		Discussion	
14:20 - 14:40		Coffee Break	
14:40 - 15:10		Cervical (4)	Moon Soo Park <i>(Korea)</i> Young-Yul Kim <i>(Korea)</i>
14:40 - 14:44	P3	S086 Automated Measurement of Cervical Sagittal Parameters Using a Hierarchical Deep Learning Pipeline: A Robust Approach to C7 Obscuration on Radiographs	Dong-Ho Kang <i>(Korea)</i>
14:44 - 14:48	P4	S087 Biomechanical Analysis Comparison of Different Cervical Posterior Screw Fixation Techniques: A Finite Element Study	Joonoh Seo <i>(Korea)</i>
14:48 - 14:52	P3	S088 Vertebral Body Sliding Osteotomy as a Less Invasive Alternative to 540° Surgery for Cervical Myelopathy with Rigid Kyphosis	Sung Tan Cho <i>(Korea)</i>
14:52 - 14:56	P4	S089 Management of Primary Cervical Spine Infections: Outcomes of 59 Patients over Three Decades	Myung-Jin Sung <i>(Korea)</i>
14:56 - 15:00	P3	S090 Impact of Post-Operative Mean Arterial Pressure Maintenance Duration on Clinical Outcomes and Complications in Cervical Spinal Cord Injury Patients	Yoon Jae Cho <i>(Korea)</i>
15:00 - 15:10		Discussion	
15:10 - 15:40		Deformity (1)	Sung-Soo Kim <i>(Korea)</i> Dong-Gune Chang <i>(Korea)</i>
15:10 - 15:14	P3	S091 Impact of Enhanced Recovery After Surgery (ERAS) Protocol on Postoperative Pain and Clinical Recovery in Adult Spinal Deformity Surgery	Yu-Cheng Yao <i>(Taiwan)</i>

May 21 (Thu)

Crystal B

15:14 - 15:18	P4	S092 Risk Factors for Revision Surgery After Acute Proximal Junctional Fracture Following Adult Spinal Deformity	Tae Soo Shin (<i>Korea</i>)
15:18 - 15:22	P3	S093 Rotated Prone Lateral Anterior Column Realignment Versus Pedicle Subtraction Osteotomy for Adult Spinal Deformity: A Matched Cohort Analysis of Radiographic and Clinical Outcomes	Yu-Cheng Yeh (<i>Taiwan</i>)
15:22 - 15:26	P4	S094 Analysis of Gait in Patients with Adult Spinal Deformity Patients Using Inverse Dynamics by AnyBody Modeling System	Jin-Ho Park (<i>Korea</i>)
15:26 - 15:30	P3	S095 Correction Degree and Spinopelvic Parameters Associated with Proximal Junctional Complications: A Systematic Review and Meta-Analysis	Hyun Duck Choi (<i>Korea</i>)
15:30 - 15:40		Discussion	
15:40 - 16:10		Deformity (2)	Nam-Su Chung (<i>Korea</i>) John H. Shin (<i>USA</i>)
15:40 - 15:44	P3	S096 Utilizing Stable Vertebra on Push-Prone Traction Radiographs for the Determination of the Lowest Instrumented Vertebra: A Novel Approach for AIS Patients with Lenke Type 3C and 6C	Tinnakorn Pluemvitayaporn (<i>Thailand</i>)
15:44 - 15:48	P4	S097 Sagittal Profiles and Their Reciprocal Changes Manifesting in Proximal Junctional Kyphosis Following Deformity Correction in Adolescent Idiopathic Scoliosis	Hong Jin Kim (<i>Korea</i>)
15:48 - 15:52	P3	S098 An Innovative 3D-360° Scanning Camera Radiation-Free Device for Assessing the Trend of Adolescent Idiopathic Scoliosis Curve	Pang-Hsuan Hsiao (<i>Taiwan</i>)
15:52 - 15:56	P4	S099 Surgical Treatment of Scoliosis in NF-1: Outcomes and Complications	Wan Soo Park (<i>Korea</i>)
15:56 - 16:00	P3	S100 Where Is the Spinal Cord Located Along the Spine in Adolescent Idiopathic Scoliosis (AIS) Patients: A Magnetic Resonance Imaging (MRI) Study	Rosalind Wong (<i>Malaysia</i>)
16:00 - 16:10		Discussion	
18:00 - 20:00		Gala Dinner (Crystal Ballroom)	

07:10 - 08:00		Breakfast Symposium III	Jin-Sung Park (Korea)
07:10 - 07:25	P1	[Sponsored by HK inno.N] inno.N Prescribing Medication for Spinal Pain	Han-Dong Lee (Korea)
07:25 - 07:40	P1	[Sponsored by CG Bio] CGBIO <small>CELL & GROWTH FACTOR BIOTECHNOLOGY</small> Dual-Function Acellular Dermal Patch: A Physical Barrier Against Peridural Fibrosis with Sustained Drug Delivery for Early Postoperative Pain Control	Min-Seok Kang (Korea)
07:40 - 07:55	P1	[Sponsored by Amgen & Chong Kun Dang] AMGEN x CKD Pharm Paradigm Shift in Osteoporosis: From EVENITY to Prolia	Joonghyun Ahn (Korea)
07:55 - 08:00		Break	
08:00 - 08:30		Best Paper Candidates Presentation I (Domestic)	Jungsub Lee (Korea) Tae-Keun Ahn (Korea)
08:00 - 08:04	P1	S101 Infection-Related Outcomes After Transforaminal Lumbar Interbody Fusion Following Implementation of an Enhanced Skin-Preparation Protocol Including Hooded Surgeon Cap Use: A Single-Center Retrospective Cohort Study	Ki Hun Kim (Korea)
08:04 - 08:08	P2	S102 Effect of Smoking Cessation Duration on Fusion Quality After Single-Level Transforaminal or Posterior Lumbar Interbody Fusion	Chan-woo Kim (Korea)
08:08 - 08:12	P1	S103 Effect of Sarcopenia and Malnutrition on Spine Surgery Outcomes	Sangjun Park (Korea)
08:12 - 08:16	P2	S104 Suboptimal Lordosis Distribution Index as a Risk Factor for Adjacent Segment Degeneration After Short-Level Fusion in Degenerative Spondylolisthesis	Sung Min Kim (Korea, KHMC)
08:16 - 08:20	P1	S105 Validation of a Double-Injection Fluoroscopic Erector Spinae Plane Block (fESPB) Protocol in Lumbar Fusion: Time-Dependent Efficacy	Sung Min Kim (Korea, SNUH)
08:20 - 08:30		Discussion	
08:30 - 09:00		Best Paper Candidates Presentation II (Domestic)	Seok-Bong Jung (Korea) Dong Ju Lim (Korea)
08:30 - 08:34	P1	S106 Vertebral Rotation Discrepancy for Adding-on When Selecting the Touched Vertebra as the Lowest Instrumented Vertebra in Idiopathic Scoliosis	Hong Jin Kim (Korea)

May 22 (Fri)

Crystal A


08:34 - 08:38	P2	S107 Over-Distracted of the Disc Space: Impact on Fusion and Rod Fracture After Lateral Lumbar Interbody Fusion with Posterior Column Osteotomy for Adult Spinal Deformity	Hong-Sik Park (Korea)
08:38 - 08:42	P1	S108 Comparison of Romosozumab and Teriparatide for Early Mechanical Stabilization in Acute Osteoporotic Vertebral Compression Fractures: A Randomized Prospective Study	Jin-Hak Kim (Korea)
08:42 - 08:46	P2	S109 Cost-Utility Analysis of Endoscopic Versus Microscopic Lumbar Discectomy: A Randomized Controlled Trial-Based Economic Evaluation	Sang-Min Park (Korea)
08:46 - 08:50	P1	S110 Feasibility of Intra-Cage vs. Extra-Cage Application of Recombinant Human Bone Morphogenetic Protein-2 in Posterior Lumbar Interbody Fusion	Jun-Young Choi (Korea)
08:50 - 09:00		Discussion	
09:00 - 09:30		Best Paper Candidates Presentation III (Domestic)	Seong Jun Ahn (Korea) Chang Su Kim (Korea)
09:00 - 09:04	P1	S111 Early Dynamic Stability as a Surrogate Marker for Long-Term Success After Oblique Lumbar Interbody Fusion: A Minimum 5-Year Follow-Up Study	Sung Taeck Kim (Korea)
09:04 - 09:08	P2	S112 Radiographic Progression of Lumbar Degenerative Spondylolisthesis After Decompression Alone	Hae-Dong Jang (Korea)
09:08 - 09:12	P1	S113 Multiple Pathways to Stability: Comparative Analysis of Two Fundamentally Different Surgical Strategies in Posterior Atlantoaxial Fusion	Jeuk Lee (Korea)
09:12 - 09:16	P2	S114 Surgery-Free Survival and Risk Factors for Surgical Conversion After Diagnosis of Degenerative Cervical Myelopathy: A Nationwide Population-Based Cohort Study	Ji Uk Choi (Korea)
09:16 - 09:20	P1	S115 Posterior Cervical Foraminotomy Provides Comparable Motor Recovery to Anterior Cervical Discectomy and Fusion in Cervical Radiculopathy with Motor Weakness Despite Longer Recovery Time	Sehan Park (Korea)
09:20 - 09:30		Discussion	

09:30 - 10:00	Best Paper Candidates Presentation IV (International)	Sang-Bong Ko (<i>Korea</i>) Jae Hyuk Yang (<i>Korea</i>)
09:30 - 09:34	P1 S116 Comparison Between Lowest Instrumented Vertebra (LIV) at L3 vs. L4 in Adolescent Idiopathic Scoliosis (AIS) Patients with Major Lumbar Curves with Lower End Vertebra (LEV) at L4	Saturveithan Chandirasegaran (<i>Malaysia</i>)
09:34 - 09:38	P2 S117 Postoperative Relocation of the Thoracic Kyphosis Apex as a Risk Factor for Proximal Junctional Kyphosis: A Potentially Preventable Condition	Xiongjie Li (<i>China</i>)
09:38 - 09:42	P1 S118 Minimally Invasive Decompression for Lumbar Degenerative Disease: A Systematic Review of Biportal Endoscopic vs Open Surgery	Adrianto Perbowo (<i>Indonesia</i>)
09:42 - 09:46	P2 S119 Rethinking Ligamentum Flavum Thickening: Histopathology Challenges the Hypertrophy-Only Paradigm in Lumbar Spinal Stenosis	Ery Satriawan (<i>Indonesia</i>)
09:46 - 09:50	P1 S120 VertebriX: An Interpretable AI Framework for Opportunistic Osteoporosis Grading from Routine Spine Imaging	Sudhir Ganesan (<i>India</i>)
09:50 - 10:00	Discussion	
10:00 - 10:20	Coffee Break	
10:20 - 10:50	Best Paper Candidates Presentation V (International)	Tzai Chiu-Yu (<i>Taiwan</i>) Sang-Bum Kim (<i>Korea</i>)
10:20 - 10:24	P1 S121 Sagittal Balance and HRQOLs in Young Patients with High-Grade Dysplastic Spondylolisthesis Who Underwent Modified Harm's Technique Reduction: Long-Term Follow-Up, Single-Center Study	Appaji Krishnan Krishnamurthy (<i>India</i>)
10:24 - 10:28	P2 S122 Percutaneous Endoscopic Discectomy Versus Open Discectomy: Long-Term Reduced Risk of Spinal Fusion and Insights Across Patient Subgroups from the Real-World Global Collaborative Network	Sung Huang Laurent Tsai (<i>Taiwan</i>)
10:28 - 10:32	P1 S123 Does Segmental Kyphosis Matter in Cervical Disc Arthroplasty?	HWD Hey (<i>Singapore</i>)
10:32 - 10:36	P2 S124 A Predictive Model for Optimal L4/5 Cage Height in Oblique Lumbar Interbody Fusion: A Quantitative MRI Analysis of 282 Adults	Kritsada Puttasean (<i>Thailand</i>)

May 22 (Fri)

Crystal A

10:36 - 10:40	P1	S125 Posterior-Only Approach for Anterior Reconstruction in Dorsolumbar Spinal Tuberculosis	Arjun Dumre (<i>Nepal</i>)
10:40 - 10:50		Discussion	
10:50 - 11:20		Best Paper Candidates Presentation VI (International)	Woo Dong Nam (<i>Korea</i>) Soo Taek Lim (<i>Korea</i>)
10:50 - 10:54	P1	S126 The iLLIF Score: A Predictive Success Scoring System for Indirect Decompression in Lateral Lumbar Interbody Fusion	Ville Pongsitthichai (<i>Thailand</i>)
10:54 - 10:58	P2	S127 Impact of Poor Preoperative Nutritional Status on Residual Neuropathic Pain After Cervical Laminoplasty in Geriatric Patients	Eiji Takasawa (<i>Japan</i>)
10:58 - 11:02	P1	S128 Beyond the Disc: Clinical and Radiological Mimics of Lumbar Disc Prolapse	Shahidul Khan (<i>Bangladesh</i>)
11:02 - 11:06	P2	S129 Comparative Effectiveness of Anterior, Posterior, and Combined Surgical Approaches in Lumbar Tuberculosis: A Systematic Review and Meta-Analysis	Abdul Imran (<i>Indonesia</i>)
11:06 - 11:10	P1	S130 Sagittal Cervical Alignment and Clinical Outcomes Following Two-Level Anterior Cervical Decompression and Fusion with Plating	Kyaw Linn Linn (<i>Myanmar</i>)
11:10 - 11:20		Discussion	
11:20 - 11:40		Invited Lecture V	Bong-Soon Chang (<i>Korea</i>)
11:20 - 11:35	P1	S131 Contemporary Perspectives on Proximal Junctional Failure	Thanut Valleenukul (<i>Thailand</i>)
11:35 - 11:40		Discussion	
11:40 - 12:20		Plenary Lecture II	Kyung-Soo Suk (<i>Korea</i>)
11:40 - 12:10	P1	S132 Serendipity and Spinal Deformity Surgery	Khaled M. Kebaish (<i>USA</i>)
12:10 - 12:20		Discussion	
12:20 - 13:20		Luncheon Symposium III	Yong Chan Kim (<i>Korea</i>)
12:20 - 12:35	P1	[Sponsored by Dong-A ST]  DONG-A ST Evidence for Limaprost in the Treatment of Lumbar Spinal Stenosis	Ji-Won Kwon (<i>Korea</i>)
12:35 - 12:50	P1	[Sponsored by Daewon Pharmaceutical]  Optimizing LBP Pain Management : Multi-Modal Approach	Sang-Min Park (<i>Korea</i>)

12:50 - 13:05	P1	[Sponsored by Viatris Korea]  Optimizing Pain Control in Spine Surgery Through Multimodal Analgesia	Hae-dong Jang <i>(Korea)</i>
13:05 - 13:20		Break	
13:20 - 14:20		Symposium III Lumbar: Current Surgical Strategies and Emerging Challenges in Revision Lumbar Surgery and Thoracolumbar Burst Fractures	
13:20 - 13:58		Session 1: The Growing Burden of Revision Lumbar Spine Surgery: How Can We Do Better?	Dong-Eun Shin <i>(Korea)</i> Young-Woo Kim <i>(Korea)</i>
13:20-13:27	P1	S133 Why Are Revision Lumbar Spine Surgeries Increasing?	Jin-Ho Park <i>(Korea)</i>
13:27-13:34	P2	S134 Clinical Decision-Making and Strategic Planning in Revision Lumbar Spine Surgery	Tae-Hoon Kim <i>(Korea)</i>
13:34-13:41	P1	S135 Technical Strategies in Revision Surgery	Chang Hwa Hong <i>(Korea)</i>
13:41-13:48	P2	S136 Tailored Surgical Strategies for Revision Lumbar Spine Surgeries Based on Patient-Specific Conditions	Yong-Chan Kim <i>(Korea)</i>
13:48-13:58		Discussion	
13:58 - 14:20		Session 2: Surgical Strategies for Acute Thoracolumbar Burst Fractures	Dong Ki Ahn <i>(Korea)</i> Hun Kyu Shin <i>(Korea)</i>
13:58-14:03	P1	S137 Is Spinal Fusion Always Necessary for Thoracolumbar Burst Fractures?	Ki-Han You <i>(Korea)</i>
14:03-14:08	P2	S138 Short-Segment Fixation vs. Long-Segment Fixation: Biomechanical and Clinical Considerations	Jae Hwan Cho <i>(Korea)</i>
14:08-14:13	P1	S139 Percutaneous MIS ligamentotaxis - Thoracolumbar Osteoporotic Bursting Fracture	Seong-Jun Ahn <i>(Korea)</i>
14:13-14:20		Discussion	
14:20 - 14:40		Invited Lecture VII	Yong-Soo Choi <i>(Korea)</i>
14:20 - 14:35	P1	S140 Fluoroscope Guided Percutaneous Cement Augmentation for Proximal Junctional Failure After Long Spinal Fusion	Tsai-Sheng Fu <i>(Taiwan)</i>
14:35 - 14:40		Discussion	



May 22 (Fri)

Crystal A

14:40 - 15:00	Coffee Break	
15:00 - 15:30	Lumbar (3)	Hong Moon Sohn (Korea) Hansol Lee (Korea)
15:00 - 15:04	P1 S141 Improved Keel Position Accuracy in Robot-Navigated Lumbar Disc Replacement	Zhihong Chew (Singapore)
15:04 - 15:08	P2 S142 Predictors of Cage Subsidence After Oblique Lumbar Interbody Fusion	Won Seok Kim (Korea)
15:08 - 15:12	P1 S143 Association of Gut Dysbiosis With Lumbar Intervertebral Disc Degeneration: A Cross-Sectional Study	Gurudip Das (India)
15:12 - 15:16	P2 S144 Intraoperative Venogram-Assisted Removal of Malpositioned Pedicle Screw Encroaching the Common Iliac Vein: Technical Note	Chang-Geun Yu (Korea)
15:16 - 15:20	P1 S145 2D-Fluoroscopy Based Robotic Assisted Guidance System for Pedicle Screw Placement in Thoracolumbar Spine Surgery: Technical Note and Preliminary Case Report	Jae-Hyoun Koh (Korea)
15:20 - 15:30	Discussion	
15:30 - 16:00	Lumbar (4)	Sung-Woo Choi (Korea) Jae Hwan Cho (Korea)
15:30 - 15:34	P1 S146 Functional Outcome of Transforaminal Endoscopic Lumbar Discectomy: Experience of My Early 25 Cases in Nepal	Jitendra Thakur (Nepal)
15:34 - 15:38	P2 S147 Does Endoscope Angle Influence Outcomes in ULBD: A Comparison of 0° and 30° Endoscopes for Lumbar Spinal Stenosis	Hyung-Rae Lee (Korea)
15:38 - 15:42	P1 S148 Redefining Prognosis in Cauda Equina Syndrome: Why Aetiology and Level Matter More Than Timing	R S Chahal (India)
15:42 - 15:46	P2 S149 Sacroiliac Joint Vacuum Phenomenon as a Potential Predictor of Poor Outcomes After Short-Segment Lumbar Fusion	Wan Soo Park (Korea)
15:46 - 15:50	P1 S150 The Correlation of Iliac Crest Morphology and Safe Working Zone for Lateral Lumbar Interbody Fusion	Pilan Jaipanya (Thailand)
15:50 - 16:00	Discussion	

16:00 - 16:40	Traveling Fellowship & Asian Spine Society Visiting Reports	
16:00 - 16:22	Traveling Fellowship Reports	
16:00 - 16:11	P1 Japan	Dae-Woong Ham (<i>Korea</i>)
16:11 - 16:22	P1 Taiwan	Sub-Ri Park (<i>Korea</i>)
16:22 - 16:40	Asian Spine Society Visiting Reports	
16:22 - 16:28	P1 India	Byung Wan Choi (<i>Korea</i>)
16:28 - 16:34	P1 Thailand	Byung Ho Lee (<i>Korea</i>)
16:34 - 16:40	P1 Malaysia (APSS)	Jiwon Park (<i>Korea</i>)
16:40 - 17:00	Best Paper Awards	
17:00 - 17:10	Closing Remarks	
17:10 - 17:20	Farewell and Inauguration Ceremony for the President of KSSS	

May 22 (Fri)**Crystal B**




07:10-08:00		Breakfast Symposium IV	Suk-Joong Lee (Korea)
07:10-07:25	P3	[Sponsored by GS Medical]  My Transformative Executive MBA Journey as a Neurosurgeon	John H. Shin (USA)
07:25-07:40	P3	[Sponsored by Myungmoon Pharm Co., Ltd]  Myungmoon Pharm Improving Patient Compliance in Spinal Pain Management: The Role of Fixed-Dose Combinations	Tae-Keun Ahn (Korea)
07:40 - 08:00		Break	
08:00 - 08:30		Deformity (3)	Jung-Hee Lee (Korea) Joonghyun Ahn (Korea)
08:00 - 08:04	P3	S151 Pedicle Subtraction Osteotomy for Adult Spinal Deformity: A Comparative Analysis of Perioperative Safety and Radiographic Efficacy in Primary vs. Revision Settings	Swayam Dash (India)
08:04 - 08:08	P4	S152 Incidence and Risk Factors of Revision Surgery with Acute Proximal Junctional Failure After Anterior Column Realignment for Adult Spinal Deformity	Jin-Sung Park (Korea)
08:08 - 08:12	P3	S153 Postoperative Thoracic Muscle Atrophy Is Associated with Delayed Proximal Junctional Kyphosis Following Adult Spinal Deformity Surgery: A Level-Specific Analysis	Se-Hyeon Jeon (Korea)
08:12 - 08:16	P4	S154 Comparative Analysis of Three Lordosis Correction Parameters for Predicting Proximal Junctional Kyphosis in Adult Spinal Deformity Surgery	Se-Jun Park (Korea)
08:16 - 08:20	P3	S155 Sequential Rod Insertion Strategy After Anterior and Posterior Surgery to Minimize Coronal Imbalance in Degenerative Lumbar Kyphoscoliosis	Hyun-Jun Kim (Korea)
08:20 - 08:30		Discussion	
08:30 - 09:00		Deformity (4)	Chang Ju Hwang (Korea) Kun Bo Park (Korea)
08:30 - 08:34	P3	S156 Managing Scoliosis in Immunocompromised Patients with Hyper-IgE Syndrome: Evidence Review and Suggested Protocol	Ahmad Roslan (Malaysia)
08:34 - 08:38	P4	S157 Impact of Declining Birth Rates on the Temporal Trend in the Prevalence of Idiopathic Scoliosis in South Korea: An Analysis of School-Based Screening Data, 2008–2023	Sun Woo Lee (Korea)

08:38 - 08:42	P3	S158 The Changes of Muscle Character During Treatment of Adolescent Idiopathic Scoliosis	Heon Jung Park (<i>Korea</i>)
08:42 - 08:46	P4	S159 A Novel and Simple Technique to Correct Shoulder Balance in Patients Undergoing Surgery for Adolescent Idiopathic Scoliosis	Mubashar Bajwa (<i>Pakistan</i>)
08:46 - 08:50	P3	S160 The Price of Straightening Spines: Comparative Financial Burden of Adolescent Idiopathic Scoliosis and Congenital Scoliosis Surgery in a Tertiary Care Centre in a Third World Country	Tejaswin Jha (<i>India</i>)
08:50 - 09:00		Discussion	
09:00 - 09:30		Basic Research (1)	Jae Hyuk Shin (<i>Korea</i>) Junseok Lee (<i>Korea</i>)
09:00 - 09:04	P3	S161 Finite Element Analysis of Stress Variation in Adjacent Vertebrae and Intervertebral Discs After Vertebroplasty for Osteoporotic Vertebral Compression Fractures	Sudhir Ganesan (<i>India</i>)
09:04 - 09:08	P4	S162 Automated Measurement of Cervical Sagittal and Local Parameters Using a Generalizable Deep Learning Model: A Multi-national Development and Validation Study	Dong-Ho Kang (<i>Korea</i>)
09:08 - 09:12	P3	S163 Brain-Derived Neurotrophic Factor (BDNF) Enhances Osteogenesis of Bone Marrow-Derived Stromal Cells Through P38 MAPK Signaling Pathway	Woo-Kie Min (<i>Korea</i>)
09:12 - 09:16	P4	S164 AI-Driven Patient-Specific Spinal Digital Twin for Spine Healthcare: Proof-of-Concept Research	Junseo Kim (<i>Korea</i>)
09:16 - 09:20	P3	S165 Dynamic Variability of Pelvic Incidence in Weight-Bearing 3D CT: A Spinopelvic Analysis in Elderly Patients	Subin Lim (<i>Korea</i>)
09:20 - 09:30		Discussion	
09:30 - 10:00		Basic Research (2)	Ki Youn Kwon (<i>Korea</i>) Sang-Il Kim (<i>Korea</i>)
09:30 - 09:34	P3	S166 Thrombospondin-1 Plays a Role in Intervertebral Disc Aging and Degeneration	Yuan Fu Liu (<i>Taiwan</i>)
09:34 - 09:38	P4	S167 Deep Learning Architectures for Surgical Instrument Segmentation in Endoscopic Spine Surgery: A Comparative Evaluation of Foundation Models and Task-Specific Approaches	Bong-Su Mun (<i>Korea</i>)
09:38 - 09:42	P3	S168 Synthetic MRI of the Spine – Reconstruction from CT and In Vivo Validation	Sangjun Park (<i>Korea</i>)

May 22 (Fri)

Crystal B

09:42 - 09:46	P4	S169 Preclinical Evaluation of a Pulsed Electromagnetic Field (PEMF) Device for Enhancing Bone Regeneration in a Rat Defect Model	Dongmyung Eun (Korea)
09:46 - 09:50	P3	S170 Rotation-Related Deviation in Pelvic Incidence Measurement: A Three-Dimensional Analytical Study	Jae Hyuk Shin (Korea)
09:50 - 10:00		Discussion	
10:00 - 10:20		Coffee Break	
10:20 - 10:50		Tumor	Chang-Bae Kong (Korea) Sam Yeol Chang (Korea)
10:20 - 10:24	P3	S171 The Learning Curve of Total En Bloc Spondylectomy (TES) in a Resource-Limited Setting: A Case Series from Eastern Indonesia	Aries Hidayat (Indonesia)
10:24 - 10:28	P4	S172 Clinical Outcomes of Surgery versus Radiotherapy in Bilsky Grade 3 Metastatic Epidural Spinal Cord Compression	Kihyun Kwon (Korea)
10:28 - 10:32	P3	S173 Simultaneous Anterior-Posterior En Bloc Spondylectomy Using Rotated Prone Lateral Surgery: A Technical Note and Case Series	Yu-Cheng Yeh (Taiwan)
10:32 - 10:36	P4	S174 Risk Stratification of Spinal Metastasis in Non-Small Cell Lung Cancer Using Treatment Response-Integrated Machine Learning Survival Models	Jeuk Lee (Korea)
10:36 - 10:40	P3	S175 Intraoperative Neuromonitoring for Spinal Cord Tumors	John David Mata (Philippines)
10:40 - 10:50		Discussion	
10:50 - 11:20		Trauma	Jin Hwan Kim (Korea) Byung Ho Lee (Korea)
10:50 - 10:54	P3	S176 A New Scoring System Incorporating Hounsfield Unit Values to Predict Adjacent Vertebral Fracture After Balloon Kyphoplasty	Koji Matsumoto (Japan)
10:54 - 10:58	P4	S177 Can Short-Term Osteoporosis Medication Prevent Vertebral Height Loss in the Acute Phase of Osteoporotic Vertebral Compression Fractures? A 3-Month Longitudinal Analysis	Daehee Choi (Korea)
10:58 - 11:02	P3	S178 Comparison of Effectiveness of Pedicle Screw with Polyaxial/Monoaxial Conversion Capabilities with Conventional Pedicle Screws in the Reduction of Focal Kyphosis of Burst Fracture	Yu Chung Wong (Hong Kong)
11:02 - 11:06	P4	S179 Comparison of Surgical Outcomes Between Single Day A-P and Staged P-A Approach in Traumatic Thoracolumbar Fractures	Hee-Woong Chung (Korea)

11:06 - 11:10	P3	S180 Impact of Anti-osteoporosis Medication on Refracture Prevention Following Osteoporotic Vertebral Fracture: A Systematic Review and Meta-analysis	Hyungsub Jin (Korea)
11:10 - 11:20		Discussion	
11:20 - 11:40		Invited Lecture VI	Kyu Jung Cho (Korea)
11:20 - 11:35	P3	S181 Awake Robotic Spinal Fusion – A New Paradigm in Minimally Invasive Spine Surgery	Shree Kumar Dinesh (Singapore)
11:35 - 11:40		Discussion	
12:20 - 13:20		Luncheon Symposium IV	Sang-Bum Kim (Korea)
12:20 - 12:35	P3	[Sponsored by Daewoong Pharmaceutical & Celltrion Pharm]   The New Era of Osteoporosis Treatment with Denosumab (STOBOCLO)	Tae-Keun Ahn (Korea)
12:35 - 12:50	P3	[Sponsored by Daiichi Sankyo]  Daiichi-Sankyo Practical Use of Mirogabalin in Spinal Disorders: New Data and Clinical Insights	Jun-Young Choi (Korea)
12:50 - 13:20		Break	
13:20 - 14:20		Symposium IV Deformity: Fagility and ERAS in Spinal Deformity Surgery	Seung Woo Suh (Korea) Young-Hoon Kim (Korea)
13:20-13:32	P3	S182 Frailty in Spinal Deformity Surgery: Why It Matters More Than Age	Joonghyun Ahn (Korea)
13:32-13:44	P4	S183 ERAS in Pediatric Spinal Deformity Surgery	Sam Yeol Chang (Korea)
13:44-13:56	P3	S184 ERAS in Adult Spinal Deformity Surgery	Hee-Woong Chung (Korea)
13:56-14:08	P4	S185 AI-Based Spinal Deformity Surgery	Ji-Won Kwon (Korea)
14:08-14:20		Discussion	
14:20 - 14:40		Invited Lecture VIII	Jae Hyup Lee (Korea)
14:20 - 14:35	P3	S186 Management Strategies in Pediatric Spinal Tubercular Deformity Correction	Sudhir Kumar Srivastava (India)
14:35 - 14:40		Discussion	

May 22 (Fri)

Crystal B

14:40 - 15:00	Coffee Break	
15:00 - 15:30	Infection	Hwa-Yeop Na (Korea) Byung Wan Choi (Korea)
15:00 - 15:04	P3 S187 Efficacy and Modality of Antibiotics Administration Within 24 Hours After Spine Surgery	Sangjun Park (Korea)
15:04 - 15:08	P4 S188 Neurological Recovery After Surgical Intervention in Neglected Spinal Tuberculosis with Long-Standing Neurological Deficits: A Retrospective Case Series	Hamzah (Indonesia)
15:08 - 15:12	P3 S189 Tuberculous Spondylodiscitis During Pregnancy: Challenges and Lessons From Two Case Reviews	Ahmad Roslan (Malaysia)
15:12 - 15:16	P4 S190 Clinical Outcomes of Surgical Management in Spinal Tuberculosis: A 11-Year Retrospective Study from a Tertiary Care Center	Ram Barakoti (Nepal)
15:16 - 15:20	P3 S191 Climatic Risk Factors for Surgical Site Infection Across Orthopedic Procedures: A Multicenter Big Data Study	Sangjun Park (Korea)
15:20 - 15:30	Discussion	
15:30 - 16:00	Infection & Miscellaneous	Jung Pil Heo (Korea) Se-Jun Park (Korea)
15:30 - 15:34	P3 S192 Outcomes of Spine Surgery in Chronic Liver Failure Patients at a Tertiary Care Liver Transplant Center: A 10-Year Retrospective Analysis	Phani Kiran Surapuraju (India)
15:34 - 15:38	P4 S193 Development of a Rabbit Model for Investigating Biofilm Formation in Implant Infections	Gilbert Dimacali (Philippines)
15:38 - 15:42	P3 S194 Early Surgical Stabilisation Significantly Improves Outcomes in Spinal Tuberculosis (Pott's Disease)	Alamgir Hossain (Bangladesh)
15:42 - 15:46	P4 S195 Evolution of Surgical Strategy in Unilateral Biportal Endoscopy for Extensive Spinal Epidural Abscess: From Multi-level Decompression to Limited Approach with Catheter Drainage	Dong Ha Kim (Korea)
15:46 - 15:50	P3 S196 Epidemiological and Microbiological Profile of Spine Infection in Northern Malaysia: A 5-Year Retrospective Study	Sobri Nor (Malaysia)
15:50 - 16:00	Discussion	

e-Poster Session

The e-Posters will be displayed electronically on laptops provided at the venue. These laptops will be available for continuous viewing throughout the event, allowing attendees to browse the e-Posters at their convenience.

- 08:00-17:00, May 21 (Thu) - 22 (Fri), 2026
- Emerald Room Foyer (2F)

Poster Code	Abstract No.	Title	Presenter
E001	2026S-007	10-Year Follow-Up of Watertight Dural Patch Repair for an Iatrogenic Dural Defect During Spinal Intradural Arachnoid Cyst Excision: A Case Report	Joonil La <i>(Korea)</i>
E002	2026S-008	Unstable C1-C2 Fracture Dislocation in an Elderly Patient: A Case Report	Ma. Gicelle Christine Ambulo <i>(Philippines)</i>
E003	2026S-015	Amendment for Progressive Kyphotic Deformity in Spinal Tuberculosis: Challenges and Outcomes	Saifullah Al Noman <i>(Bangladesh)</i>
E004	2026S-016	Clinical Outcomes and Cost-Effectiveness of Demineralized Bone Matrix-Augmented Vertebroplasty for Osteoporotic Vertebral Compression Fractures	Seung Myung Wi <i>(Korea)</i>
E005	2026S-017	An Obstetrical and Gynaecological Insight to Measure the Gender-Specific Issues Including Menstrual Disorders in Patients with Scoliosis – A Genuine Step Towards Empowering Women’s Inclusive Health	Tejaswin Jha <i>(India)</i>
E006	2026S-020	Association Between ABO Blood Group and Risk of Adolescent Idiopathic Scoliosis in Surgically Treated Patients: A Case-Control Study	Tejaswin Jha <i>(India)</i>
E007	2026S-045	Clinical and Microbiological Characteristics of Pyogenic Spondylodiscitis: A Retrospective Study	Nirajan Subedi <i>(Nepal)</i>
E008	2026S-061	Delayed Presentation of Pediatric Atlantoaxial Subluxation with Cervical Myelopathy After Clavicle Fracture - A Case Report	Dong-Hwan Kim <i>(Korea)</i>
E009	2026S-075	Tuberculous Spondylitis Following Percutaneous Endoscopic Lumbar Discectomy (PELD): A Case Report	Ma. Gicelle Christine Umali Ambulo <i>(Philippines)</i>
E010	2026S-078	Evaluation of Deep Learning for Scoliosis Pre-Screening Using Preprocessed Chest X-ray Images	Min-Gu Jang <i>(Korea)</i>
E011	2026S-083	Measurement of Lumbar Lordosis Using a Deep Learning-Based Artificial Intelligence Model	Seong Ho Oh <i>(Korea)</i>

Poster Code	Abstract No.	Title	Presenter
E012	2026S-084	Deep Learning–Based AI Analysis of the Correlation Between Lumbar Lordosis and Age	Seong Ho Oh (<i>Korea</i>)
E013	2026S-085	Is There Correlation Between Kyphotic Deformity and Pain in Thoracolumbar Osteoporotic Compression Fractures?	Byeongwook Jang (<i>Korea</i>)
E014	2026S-097	Contextualizing Chest Radiograph-Based Pulmonary Function Estimation in Scoliosis Using Multimodal Deep Learning	Beomsu Kim (<i>Korea</i>)
E015	2026S-100	Fusion Outcomes Following Two-Level Anterior Cervical Decompression and Fusion with Autologous Iliac Crest Bone Graft and Plating	Kyaw Linn Linn (<i>Myanmar</i>)
E016	2026S-102	Clinical Profile of Chronic Low Back Pain Patients After Unilateral Biportal Endoscopic (UBE) Spine Surgery: A Retrospective Cohort Study	Ma. Ella Muriel Valdevieso (<i>Philippines</i>)
E017	2026S-104	Unilateral Biportal Endoscopic (UBE) for Preservation of Flip Flavum Ligament in Lumbar Herniated Disc Herniation	T Arief Dian (<i>Indonesia</i>)
E018	2026S-120	Impact of Polyester Mesh-Containing Tissue Adhesive on C-Reactive Protein Kinetics and Antibiotic Stewardship in Instrumented Spinal Fusion	Yoon Jae Cho (<i>Korea</i>)
E019	2026S-132	Temporary Internal Distraction, a Softer Alternative to Severe Rigid Scoliosis: Early-Onset Scoliosis with Delayed Treatment	Romel Paredes Estillore (<i>Philippines</i>)
E020	2026S-139	Biportal Endoscopic Spinal Surgery via Interlaminar Approach for Symptomatic Conjoined Nerve Root: A Technical Note and Case Series	Doheon Kim (<i>Korea</i>)
E021	2026S-147	Novel Use of Combined Spinal and Erector Spinae Plane Block for Long Segment Thoracolumbar Fusion	Choong Hoon Foo (<i>Malaysia</i>)
E022	2026S-151	Outcomes of Posterior Indirect Decompression in Acute Thoracolumbar Burst Fracture with Incomplete Neurological Deficit	Maung Lwin (<i>Myanmar</i>)
E023	2026S-154	Biportal Endoscopic TLIF at L5–S1 Isthmic Spondylolisthesis: Technical Strategies for Anterior Column Support and Segmental Lordosis Restoration	Yujin Kim (<i>Korea</i>)

Poster Code	Abstract No.	Title	Presenter
E024	2026S-158	Prevalence of Tandem Spinal Stenosis in Korean Males Over the Past 10 Years	Sang Chun <i>(Korea)</i>
E025	2026S-161	Long-Term MRI Assessment of Multifidus Muscle Changes Following Biportal Endoscopic Spinal Surgery	Youngjoon Ryu <i>(Korea)</i>
E026	2026S-170	Surgical Strategies for Osteoporotic Vertebral Fractures: Balancing Stability and Biology	Shahnawas <i>(Bangladesh)</i>
E027	2026S-178	The Surgical Learning Curve and Technical Evolution Across 100 Levels of Cervical Disc Replacements	Leong Dalun <i>(Singapore)</i>
E028	2026S-181	Massive Pleural Effusion and Ascites Causing Decompensated Respiratory Failure Following Biportal Endoscopic Spine Surgery in Multilevel Degenerative Lumbar Pathologies: A Case Report	Jae Young Kim <i>(Korea)</i>
E029	2026S-182	Infectious Spondylitis with L1 Collapse Caused by Methicillin-Resistant Staphylococcus Argenteus in a Patient with Crohn's Disease Treated with Expandable Cage and Posterior Instrumentation: A Case Report	Byeong Heon Choi <i>(Korea)</i>
E030	2026S-183	Microscopic Lumbar Foraminal Decompression via Wiltse Approach for Foraminal or Extraforaminal Stenosis: Risk Factor Analysis for Poor Outcome	Eun-Min Seo <i>(Korea)</i>
E031	2026S-184	Triple Level Cervical Disc Arthroplasty: An Effective Alternative to ACDF or Hybrid Procedures in Multilevel Cervical Degenerative Disc Disease	Jun Rui Don Koh <i>(Singapore)</i>
E032	2026S-191	Outcomes of Vertebroplasty Versus Conservative Treatment of Acute Osteoporotic Vertebral Fracture	Sai Rath <i>(Myanmar)</i>
E033	2026S-199	Microsurgical Resection of a Thoracolumbar Dumbbell-Type Schwannoma With Preservation of the Functional Nerve Root	Jae Hyuk Shin <i>(Korea)</i>

Video Session


Video presentations offer a more visual way to learn new and innovative techniques in spine surgery. All participants are invited to join the video session throughout the conference. The videos will be played on a large LED screen in the Emerald Room. Alternatively, you may choose and watch any video at your convenience using laptops in the e-Poster Session, located in the Emerald Room Foyer.

- 08:00-17:00, May 21 (Thu) - 22 (Fri), 2026
- Emerald Room & Foyer (2F)

Topic	Title	Presenter
Cervical	Cervical Laminoplasty	Kyung-Soo Suk <i>(Korea)</i>
	Vertebral Body Sliding Osteotomy	Dong-Ho Lee <i>(Korea)</i>
	Spinal Cord Tumors	Jae Hyuk Shin <i>(Korea)</i>
	Anterior Vertebral Artery Mobilization and Oblique Corpectomy for Cervical Dumbbell Tumor	Hyoungmin Kim <i>(Korea)</i>
Thoracic	Minimally Invasive Surgical Management for Thoracic Spine Pathology	JooYoung Lee <i>(Korea)</i>
Lumbar	Biportal Endoscopic Revision Surgery After Lumbar Spine Surgery: Tailored Approaches for Diverse Failure Situations	Seung-Hyun Choi <i>(Korea)</i>
MIS	Prone Single-Position OLIF with ACR Technique and O-arm-Guided PPF	Jin-Sung Park <i>(Korea)</i>
	Technical Tips for Anatomic Reduction of Spondylolytic Spondylolisthesis Using Biportal Endoscopic Approach	Min-Seok Kang <i>(Korea)</i>
Deformity	Anterior-Posterior Combined Surgery for ASD	Nam-Su Chung <i>(Korea)</i>
	O-arm-Guided Pedicle Screw Placement in AIS Surgery	Ji-Won Kwon <i>(Korea)</i>
Tumor	Multilevel Total Enbloc Spondylectomy for Thoracic Spinal Sarcoma Involving T10-T12	Se-Jun Park <i>(Korea)</i>
	Removal of Intradural Dumbbell Tumor Using Dual Separate-Dural-Incision	Sam Yeol Chang <i>(Korea)</i>

Venue Information

3rd Floor



Sapphire Ballroom A

- Welcome Reception (May 20)

Pine Room

- Presidential Roundtable Meeting (May 20)


Sapphire Ballroom Foyer

- Registration Desk (May 20)
- Cocktail Reception (May 20)

Sapphire Ballroom B

- Instructional Course Lecture (ICL) (May 20)

2nd Floor



Crystal Ballroom

- Opening Remark (May 21)
- Plenary & Parallel Sessions (May 21-22)
- KSSS Research Award (May 21)
- KSSS General Assembly (May 21)
- Gala Dinner (May 21)
- Best Paper Awards (May 22)
- Farewell & Inauguration Ceremony (May 22)

Emerald Room

- Video Session (May 21-22)
- Exhibition (May 21-22)

Emerald Room Foyer

- Preview Room (May 21-22) ★
- Video & e-Poster Sessions (May 21-22) ★

Jade Room


- VIP Room (May 21-22)


Exhibition Hall

- Exhibition (May 21-22)
- Registration Desk (May 21-22)
- Photo Wall (May 21-22)

Booth Layout

2F



Booth No.	COMPANY	Booth No.	COMPANY	Booth No.	COMPANY
1, 2, 3, 4	Hanmi Pharm.	33	Corentec	53	GC.Inc
5	Medtronic KOREA LTD	34	Samjin Pharm.	54	Med Park
6, 7	SK Chemicals	35, 36, 37	VIATRIS KOREA	55	Spine Biogen
8, 9, 10, 11	CGBIO	38	HansBiomed	56	T&R Biofab
12, 13, 14, 15	AMGEN Inc. &CKD Pharm	39	Seolim	57	Sometech Inc.
16, 17	Medyssey	40	Osteonic	58	Ilyang Pharm.
18, 19, 20	DongA-ST	41	BMI Korea	59	HOW MEDICARE
21, 22, 23, 24	GS MEDICAL	42, 43	Baxter Korea	60	Alteogen Biologics
25	SeohanCare Co., Ltd	44	Han Areum Medical	61	L&C Medicare Co., Ltd.
26	Leica Microsystems	45	KDB FINANCIAL	62	MAVENS
27	Ace medicorp	46	Daewoong bio	63, 64, 65	Daewon Pharm.
28	ZEISS Korea	47, 48, 72	Daiichi Sankyo Korea	66	Celltrion Pharm
29, 30	Dalim Medical	49	MEDIPIA Co., Ltd.	67, 68, 69	Daewoong Pharm.
31	Myungmoon Pharm	50	LG Chemistry	70, 71	HK inno.N
32	Chodang Pharm.	51	Kyongbo pharm		Coffee Booth
		52	Alpha AI		

Conference Information

Registration

All participants are required to wear their badges throughout the Conference. Failure to do so may result in limited access to sessions, exhibitions, and other activities.

Operating Hours and Locations:

- 3F Sapphire Ballroom Foyer, 12:00 – 18:00, May 20 (Wed), 2026
- 2F Exhibition Hall, 06:30 - 18:00, May 21 (Thu) / 06:30 - 17:30, May 22 (Fri), 2026

Registration Fee Includes:

- Admission to all sessions & exhibition
- Access to the Welcome Reception & Gala Dinner
- Daily breakfast, lunch, and coffee breaks
- Congress kit, including the program book

On-site Registration Fee

On-site registration will be available during the congress with the following registration fees. Please note that on-site registration only accepts credit card payments (VISA, Master, JCB, and AMEX).

Category	Registration Fee
KSSS Member MD	USD 160 (KRW 200,000)
KSSS Non-Member MD	USD 180 (KRW 220,000)
Residents or Equivalents*	USD 120 (KRW 140,000)

*Equivalents: Army doctors, nurses, researchers, and medical students

Video & e-Poster Session

The e-Posters will be displayed electronically on laptops. Please note that e-Poster presenters do not have designated presentation times. The videos will be played on a large LED screen in the Emerald Room. Alternatively, you may browse and watch any video at your convenience using laptops in the Video & e-Poster session.

Video & e-Poster Session

- 08:00 - 17:00, May 21 (Thu) - 22 (Fri), 2026
- Emerald Room Foyer (2F)

Video Session

- 08:00 - 17:00, May 21 (Thu) - 22 (Fri), 2026
- Emerald Room & Foyer (2F)

Preview Room

All speakers (excluding e-Poster and Video presenters) must check in at the Preview Room at least 2 hours before their session. If your presentation is scheduled in the morning on May 21, please make sure to visit the preview room at 6:30 AM to avoid any delays. Presentation files can be checked and edited on-site, which is especially important if they contain video or audio.

- 06:30 - 17:00, May 21 (Thu) - 22 (Fri), 2026
- Emerald Room Foyer

Breakfast

A semi-buffet will be provided for the Breakfast Symposium, proudly sponsored by our Diamond, Gold, and a Silver sponsor.

- 07:10 - 07:50, May 21 (Thu), 2026
- 07:10 - 08:00, May 22 (Fri), 2026
- Crystal Ballroom A & B

Lunch

Lunch boxes, sponsored by our Diamond and Platinum sponsors, will be provided during the Luncheon Symposium.

- 11:50 - 12:30, May 21 (Thu), 2026
- 12:20 - 13:20, May 22 (Fri), 2026
- Crystal Ballroom A & B

Souvenir: Create Your Own Luggage Tag

We're offering hand-printed, custom leather luggage tags to the first 200 participants – available on a first-come, first-served basis. Each tag is personalized with engraved initials, making it a unique keepsake from the event.

- 09:00 - 16:00, May 21 (Thu) - 22 (Fri), 2026
- Athene Garden (3F)

Souvenir: 1-Minute Caricature

Stop by to get a quick, fun, and personalized hand-drawn portrait. It takes only a minute but will leave you with a lasting memory of this year's congress. Come and join us to capture your smile!

- 17:00 - 20:00, May 20 (Wed), 2026
- Sapphire Ballroom Foyer
- 17:00 - 20:00, May 21 (Thu), 2026
- Emerald Room Foyer

Social Programs

Welcome Reception

Connect with fellow participants and enjoy a delightful evening of networking, food, and drinks — a great opportunity to build professional relationships and friendships.

- 18:00 - 20:00, May 20 (Wed), 2026
- Sapphire Ballroom, 3F
- Cocktail Reception: 17:10 - 18:00 at Sapphire Ballroom Foyer, 3F

Gala Dinner

Celebrate with us at the Gala Dinner in the elegant Crystal Ballroom. After the cocktail reception, enjoy a memorable evening of fine dining and great company.

- 18:00 - 20:00, May 21 (Thu), 2026
- Crystal Ballroom, 2F
- Cocktail Reception: 17:00 - 18:00 at the Exhibition Hall, 2F

Best Paper Awards

- 16:40 - 17:00, May 22 (Fri), 2026
- Crystal Ballroom A, 2F

Farewell and Inauguration Ceremony for the President of KSSS

- 17:10 - 17:20, May 22 (Fri), 2026
- Crystal Ballroom A, 2F

Stamp Tour Event

We invite all participants to become explorers! Visit every exhibition booth, collect your stamps, and enter our exciting lucky draw for a chance to win great prizes.

How to Participate

STEP 1 Get Your Daily Card

The event runs for both days! Please note that the card colors change each day. Visit the Registration Desk every morning to pick up the correct card for the corresponding day.

STEP 2 Collect Your Stamps

Visit ALL exhibition booths in the Exhibition Hall to collect your stamps using the card you received.

STEP 3 Submit Your Card

Once you have collected all stamps, submit your completed card back to the Registration Desk.

STEP 4 Win Big at the Lucky Draw!


Don't miss the Lucky Draw session! Please remember that only on-site participants are eligible to claim prizes.

Lucky Draw #1 at the Gala Dinner

- 18:00 - 20:00, May 21 (Thu), 2026
- Crystal Ballroom

Lucky Draw #2 at the Best Paper Awards

- 16:40 - 17:00, May 22 (Fri), 2026
- Crystal Ballroom A



Destinations Within Walking Distance of Lotte Hotel Seoul



Deoksugung Palace

Deoksugung Palace is one of the five royal palaces remaining in Seoul. Mainly built near the turn of the 20th century, Deoksugung is the smallest of Seoul's palaces. The name Deoksugung means "Palace of Virtue and Longevity," signifying prayers for the long life of Emperor Gojong. Located at the corner of one of Seoul's busiest downtown intersections, Deoksugung Palace is famous for its elegant stone-wall road.



Myeong-dong

Myeong-dong is one of Seoul's premier shopping districts and is a must-see for tourists. However, it is more than just a shopping destination; Myeong-dong is also a hub of commerce, banking, and culture, with a daytime population of 1.5 to 2 million. For shoppers, there is a mixture of street stalls and retail outlets selling everything from high fashion to casual attire, as well as many Korean cosmetics stores offering high-quality products at competitive prices.



Gyeongbokgung Palace

Gyeongbokgung Palace is the principal palace of the Joseon Dynasty, built in 1395 (the fourth year of King Taejo's reign) following the relocation of the capital to Hanyang after the founding of the dynasty in 1392. Situated at the center of Hanyang, the palace was constructed against the backdrop of Baegaksan Mountain (now Bugaksan Mountain) to the north, with the wide Yukjogeori Street (now Sejong-ro) extending from its main entrance, Gwanghwamun Gate.



Insa-dong

Insa-dong, located in the heart of the city, is a significant cultural destination where precious traditional artifacts are displayed. The district features a main road lined with intricate alleys. Within these alleys, visitors can find various galleries, traditional restaurants, teahouses, and cafes. The galleries serve as the heartbeat of Insa-dong, with approximately 100 establishments offering a diverse range of traditional Korean fine arts, from paintings to sculptures.

Special Thanks to Our Sponsors

DIAMOND



PLATINUM



GOLD




SILVER



하루 2번¹ 조인스에프정 300^{mg}

다양한
임상적
근거²⁻⁷



통증 감소와 연골 보호*의
이중효과!⁸

*4상 임상시험 통해 최대 2년간의 장기 투여 시 연골 보호 효과 가능성 확인

References 1. 조인스에프정 국내 허가사항 [최신 개정일자: 2023.12.21] 2. 대한슬관절학회. 슬관절학 Arthrology of the Knee. 4th Edition. 903-931p. 3. 대한통증학회. 통증의학 Textbook of Pain Medicine. 6th Edition. 249p. 4. 대한류마티스학회. 류마티스학. KCR Textbook of Rheumatology, 3rd Edition. 454p. 5. 가톨릭대학교 의과대학 내과학교실. 임상진료지침. Current Principles and Clinical Practice of Internal Medicine. 5th Edition. 918p. 6. Jung YB, et al. four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: A herbal antiarthritic agent versus diclofenac in osteoarthritis of the knee. Am J Chin Med 2004;32(2):291-301. 7. Park YB, et al. Efficacy and Safety of Celecoxib and a Korean SYSADOA (JOINS) for the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. J Clin Med. 2025 Feb 7;14(4):1036. 8. Kim Ji, et al. Efficacy of JOINS on Cartilage Protection in Knee Osteoarthritis: Prospective Randomized Controlled Trial. Knee Surg Relat Res 2017;29(3):217-224.

제품요약정보 [제품명] 조인스에프정300밀리그램 [원료약품 및 분량] 이 약 1정 중 조인스에프정 유효성분 워링선·갈루근·하교조 30%에탄올추출액(40-1) (별규) - 300 mg [효능효과] 골관절증(퇴행성 관절질환)의 증상 완화 [용법용량] 성인·1회 1정을 1일 2회 경구투여한다. [사용상의주의사항] 1. 다음 환자에는 신중히 투여할 것. 1) 감염성대 또는 감염의 원인이 있는 환자(감염에 대한 자체 저항력이 감소될 가능성이 있음)을 고려해야 하며, 이런 경우에는 감염의 진행을 억제하는 조치를 취해야 한다. 2) 임부 또는 임신하고 있을 가능성이 있는 여성 및 수유부 3) 이 약(워링선·갈루근·하교조) 성분과 과민증이 있는 자 (후략) [제조자] 에스케이케이미칼(주) 충청북도 청주시 흥덕구 신당로 149 [판매자] 에스케이케이미칼(주) 경기도 성남시 분당구 판교로 310 ※처방하기 전 제품설명서 전문을 참고하십시오.

Product Information 조인스에프정300밀리그램
최신 허가사항에 대한 정보는 QR 코드 또는 식품
의약품안전처 의약품 안전나라(<https://nedrug.mfds.go.kr>)에서 확인할 수 있습니다




SK 케미칼

SK케미칼(주) 경기도 성남시 분당구 판교로 310
TEL 080-021-3131 www.skchemicals.com/ls


조인스에프정
300mg

ARTeMIS[®] Art of MIS

Minimally Invasive Spinal Fixation System



Sealfix™



SUPERIOR ATTACHMENT

PEG 기반의 접착력이 강화된 매트릭스



RELIABLE HEMOSTATIC PERFORMANCE

콜라겐 스펀지층의 지혈능, 적용 후 약 30초~2분 뒤 출혈이 멈춘 것을 확인



SOFT & FLEXIBLE MATERIAL

부드럽고 유연한 제형을 통한 용이한 적용



USER-FRIENDLY DESIGN

앞뒤 확인에 용이한 디자인, 적용 시 수화 불필요한 제품



SAFETY & BIOCOMPATIBILITY

바이러스 감염 및 면역반응 발생 가능성이 낮고 생체에 적합한 제품

Sealfix™

품목명: 흡수성 체내용 지혈용품 (4등급)

저장방법: 2~8 °C 냉장보관

사용목적: 외과수술 또는 개복술에서 조직의 지혈

사용기간: 제조일로부터 2년

사이즈: 50 mm x 50 mm

허가번호: 제허 25-189 호

[판매원] **dalim** (주)다림양행

(주)다림양행

서울시 마포구 월드컵북로 52-1

02)335-1657

[제조원] **dalim** (주)다림티센

(주)다림티센

서울시 마포구 연희로31 연남빌딩 3층-5층

02)3142-0646

Baxter

Floseal

HEMOSTATIC MATRIX

OPERATION HERO

FAST & EASY TO USE^{1,2}



KO-AS19-210002

1. Floseal hemostatic matrix 국내 제품 설명서(식품의약품안전처 [https://nedrug.mfds.go.kr] 의약품등 제품정보장 참조)
2. Tackett, Scott M., et al. "Real-world outcomes of hemostatic matrices in cardiac surgery." *Journal of cardiothoracic and vascular anesthesia* 28.6 (2014): 1558-1565.

국내 최초의 Pregabalin 25mg, 50mg¹

More than Pregabalin
카발린 캡슐
Pregabalin 25·50·75·150·300mg



Drug Information²

성분·함량

Pregabalin 25mg, 50mg, 75mg, 150mg, 300mg

효능·효과

1. 성인에서 말초와 중추 신경병증성 통증의 치료

2. 간질 : 성인에서 이차적 진전증상을 동반하거나 동반하지 않은 부분 발작의 보조제

3. 섬유근육통의 치료

용법·용량

이 약은 프레가발린으로서 1일 총 투여용량을 1일 2회로 나누어 음식물과 상관 없이 경구 투여한다. 이 약은 주로 신장으로 배설되므로, 신기능이 저하된 환자에 대해서는 용량이 조절되어야 한다. 1. 신경병증성 통증 1) 말초 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 3일 내지 7일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 2) 중추 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 1주일 후에 1일 300mg까지 증량할 수 있다. 추가로 1주일 후에 목표 1일 용량인 600mg까지 증량할 수 있다. 목표 1

일 용량에서 내약성을 나타내지 않을 경우 용량 감소를 고려할 수 있다. 2. 간질 (성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 일주일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 3. 섬유근육통: 이 약의 권장 용량은 1일 300mg~450mg이다. 이 약은 시작 용량으로 75mg씩 1일 2회(1일 150mg)를 투여하며, 유효성과 내약성에 근거하여 1주일 이내에 150mg씩 1일 2회(1일 300mg)까지 증량할 수 있다. 1일 300mg의 용량에서 충분한 유효성을 경험하지 못한 환자의 경우에는 1주일 이내에 225mg씩 1일 2회(1일 450mg)까지 증량할 수 있다. 1일 600mg의 용량에서도 임상 연구가 실시되었으나, 이 용량에서의 부가적인 유효성이나 충분한 내약성에 대한 증거는 없다. 용량 의존적인 이상반응을 고려하면, 1일 450mg을 초과하는 용량 투여는 권장되지 않는다.

사용상의 주의사항

1. 경고 1) 자살충동과 자살행동 (1) 항간질약을 복용한 환자에서 자살충동 또는 자살행동을 보이는 위험성이 증가하므로 항간질약을 치료받은 환자는 자살충동 또는 자살행동, 우울증의 발현 또는 악화 및 기분과 행동의 비정상적 변화에 대하여 모니터링되어야 한다.(2) 항간질약을 처방받은 간질과 다른 많은 질병은

그 자체가 이환 및 사망, 치료기간 동안의 자살충동과 자살행동의 위험성증가와 관련된다. 따라서 처방자는 항간질약 처방시 환자의 치료기간 동안 자살충동 또는 자살행동과 치료될 질병간의 연관성 유무 및 이 약의 유효성을 함께 고려한다. 2. 다음 환자에는 투여하지 말 것 1) 프레가발린 또는 이 약의 성분에 과민한 환자 2) 이 약은 유당을 함유하고 있으므로, 갈락토오스 불내성 (galactose intolerance), Lapp 유당분해효소 결핍증 (Lapp lactase deficiency) 또는 포도당-갈락토오스 흡수 장애 (glucose-galactose malabsorption) 등의 유전적인 문제가 있는 환자에게는 투여하면 안 된다.

* 기타 자세한 사항은 제품설명서를 참고하십시오.

inno.N

에이치케이이노엔 주식회사

충청북도 청주시 흥덕구 오송읍 오송생명2로 239

서울 지사: 서울특별시 중구 을지로 100 파인에비뉴 6, 7, 8층

http://www.inno-n.com | Tel. 080-700-8802



When the Best Meets the Best

NOVOSIS × **NOVOGRID**

rhBMP-2
with Hydroxyapatite

mADM Biopatch



Pain, **press ESC**



Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis

Low back pain

Naxozol Tab.500/20_{mg}
(Naproxen/Esomeprazole)

Prolia[®]

국내 출시 10년의 경험이 만든 오리지널의 자신감,
세대가 바뀌어도 데노수맙의 오리지널은 프롤리아[®]입니다¹



※ 2016년
국내 출시 이후
10년간 축적된 실제 임상 경험

※ 2017년
FREEDOM-Extension
10년 연구를 통해
추가적인 골절 위험 감소 효과 및
장기간 안전성 프로파일 확인¹

※ 2022년
3천 명 이상의 한국인 환자 대상
PMS 연구에서 골밀도 개선 및
안전성 프로파일 확인¹

※ 2024년
약 50만 명의
골다공증 환자 대상
RWE에서 지속적인
골절 위험 감소 효과 확인¹

PMS, post-marketing surveillance; RWE, real-world evidence.

References 1. 식품의약품안전처 의약품통합정보시스템_프롤리아프리필드시린지(데노수맙). 2. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5(7):513-523. 3. Rhee Y, et al. Endocrinol Metab (Seoul). 2022;37(3):497-505. 4. Curtis JR, et al. J Bone Miner Res. 2024;39(7):826-834.



암젠코리아유한회사 대한민국 서울특별시 중구 을지로5길 19, 페럼타워 20층 (수하동, FERRUM TOWER) Tel. 02 3434 4899
For further medical information, please contact : | 수신자 부담 : 00798 611 3554 | e-mail : medinfo.JAPAC@amgen.com



서울특별시 서대문구 홍정로 8 (홍정로 3가) TEL 02-2194-0300 FAX 02-2194-0369
소비자상담실 : 080-6776-080 (수신자 부담) 제품상세정보 : www.ckdpharm.com 참조

Product Information

처방하시기 전 하단의 QR 코드 또는 식품의약품안전처 의약품통합정보시스템
(https://nedrug.mfds.go.kr)을 통해 상세 제품정보를 참조하시기 바랍니다.



AnyPlus[®]

3D printing
PLIF cage



Smooth Wedge-Shaped Design

: Easy Insertion

Minimized Sharp Edge

: Designed smooth edge for minimizing damage

Bullet-tip Nose

: The nose designed easy to rotational insertion

Interconnected Irregular Porous Structure

: Irregular porous structure provide optimized cellular adhesion and proliferation

국내 Bisphosphonate 경구제 허가약품 중 유일
주 1회, **식사와 관계없이 복용가능**¹ Bisphosphonate

악토넬EC정 35mg

(Risedronate Sodium)

장용성 제형 & Chelating agent로

복용 Compliance 

음식물과 상호작용 ²




	악토넬 [®] EC정 35mg ³	악토넬 [®] 정 35mg ⁴	악토넬 [®] 정 150mg ⁵
성분·함량	리세드론산나트륨 35mg	리세드론산나트륨 35mg	리세드론산나트륨 150mg
효능·효과	폐경 후 여성의 골다공증 치료	1. 폐경 후 여성의 골다공증 치료와 예방 2. 남성의 골다공증 치료	폐경 후 여성의 골다공증 치료와 예방
용법·용량	주 1회 식사와 관계없이 경구투여	주 1회 경구투여 (아침식사 최소 30분 전에 복용하거나 또는 하루 중에 어떤 때라도 음식물이나 음료수의 섭취 전후로 최소 2시간 떨어져서 복용한다)	월 1회 경구투여 (충분한 흡수를 위해 하루 중 처음으로 음식물 또는 물 이외의 음료를 섭취하기 최소 30분 전에 복용한다)
제품코드	644503330	644503310	644503320

Reference

1. 악토넬EC정 허가사항 (23.06월 기준, 의약품안전나라 의약품 정보- 용법용량(성인) : 리세드론산나트륨으로서 1회 35 mg을 주 1회 식사와 관계없이 아침에 경구 투여한다.) 2. McClung MR et al. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet, Osteoporos Int, 2012 Jan;23(1):267-76. 3. 악토넬EC정 35mg 허가사항 (23년 11월 기준) 4. 악토넬정 35mg 허가사항 (23년 11월 기준) 5. 악토넬정 150mg 허가사항 (23년 11월 기준)

골다공증 치료의 연속성을 위한 순차 치료는 대웅졸레드론산주사액 이 이어받겠습니다.

1년 1회 투여로 남녀 골다공증 치료
2년 1회 투여로 폐경 후 여성 골다공증 예방



대웅제약 **대웅졸레드론산 주사액**
Zoledronic acid 5mg / 100mL

Ref.> 1. 대웅졸레드론산주사액 5mg/100mL 제품설명서_식약처 허가사항.
2. Anastasilakis AD, et al. *Calcif Tissue Int.* 2024;113(4):469-473.

※ 본 의약품은 엄격한 품질관리를 필한 제품입니다. 만약 구입시 사용기한 또는 유효기간이 지났거나 변질, 변태, 오염되었거나 손상된 의약품은 공정거래위원회 고시(소비자 분쟁해결기준)에 의거, 구입한 약국 및 의약품 판매업자를 통해 교환 또는 환불받을 수 있습니다. ※ 의약품 사용 후 부작용 발생 시, 부작용 신고 및 피해구제 신청은 한국약품안전관리원에 할 수 있습니다. 【**신청방법**】 한국약품안전관리원 ☎1644-6223 (또는 14-3330), ☎karp.drugsafe.or.kr | 대웅제약 소비자 센터 ☎080-550-8308~9(수신자 부담전화), 🌐www.daewoong.co.kr 【**신청대상**】 의약품 부작용으로 사망, 장애, 질병 피해를 입은 환자 및 유족 【**보상범위**】사망일시보상금, 장례비, 장애일시보상금, 진료비 ※ 자세한 제품 정보는 제품 설명서 및 QR 코드를 참조하시기 바랍니다.



ZO1241016M
2024.08.28



NSAIDs, 마침표를 찍어



급성통증 + 만성통증

급성 통증 염좌, 근육 및 힘줄 통증, 두통, 치통, 월경통, 피부염, 급성 상하기도 감염 등

만성 통증 골관절염, 요통, 류마티스 관절염




[성분함량] 1정 중 Pelubiprolen 45mg [성상] 연한 황색의 원형 서방성 필름코팅정 [효능효과] 다음 질환의 증상이나 징후의 완화: 골관절염, 류마티스관절염, 요통(허리통증)급성통증(예: 외상 후 통증, 원발월경통) [용법·용량] 1회 1정, 1일 2회 식후 경구투여 원발성월경통의 경우, 초기 권장 투여량은 1정, 필요시 투여 첫날에 1정추가 둘째날 부터는 필요 시, 권장량으로 1회 1정, 1일 2회 투여 [포장단위] 30정, 500정/Bottle [저장방법] 차광기밀용기, 실온(1~30℃) 보관 [사용기한] 제조일로부터 36개월

Daewon 대원제약



Mirogabalin, your choice for Balanced Efficacy & Safety Profile¹⁻³

START SMART, TITRATE with CONFIDENCE



제품정보는 QR코드를
통해 확인하세요! 🔍



P25-018-2027.01-V1

Study design | 1. This study evaluated the efficacy and safety of mirogabalin, a novel, potent, selective ligand the $\alpha 2\delta$ subunit of voltage-dependent Ca^{2+} channels, for the treatment of diabetic peripheral neuropathic pain(DPNP). During this double-blind, multisite, placebo-controlled phase III study, Asian patients aged ≥ 20 years with type 1 or 2 diabetes and DPNP were randomized 2:1:1 to a placebo, mirogabalin 15, 20 or 30mg/day for up to 14 weeks, with a 1-to 2-week titration. The primary endpoint was the change from baseline in average daily pain score(ADPS) at week, defined as a weekly average of daily pain. 2. This study investigated the safety and efficacy of mirogabalin, a novel, potent, selective ligand of the $\alpha 2\delta$ subunit of voltage-dependent Ca channels, for the treatment of postherpetic neuralgia (PHN). In this multicenter, double-blind, placebo-controlled phase 3 study, Asian patients ≥ 20 years with PHN were randomized 2:1:1 to a placebo, mirogabalin 15, 20 or 30mg/day for up to 14 weeks. The primary efficacy endpoint was the change from baseline in average daily pain score at week 14, defined as a weekly average of daily pain. 3. This randomized, double-blind, multisite, placebo-controlled, phase 3 study investigated mirogabalin efficacy and safety for the treatment of central neuropathic pain in patients with traumatic spinal cord injury. Adult patients were randomized (1:1) to receive placebo or mirogabalin. The primary efficacy endpoint was change from baseline in the weekly average daily pain score (ADPS) at week 14.

Reference | 1. Baba, Masayuki et al. "Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients."

Journal of diabetes investigation vol. 10,5 (2019) 2. Kato, Jitsu, et al. "Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients." Pain 160.5 (2019): 1175-1185. 3. Ushida, Takahiro, et al. "Mirogabalin for central neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled, phase 3 study in Asia." Neurology 100.11 (2023): e1193-e1206. 4. 탈리제[®] 허가사항 5. "탈리제 정제 이미지." 약학정보원

신경병증성 통증 1차 치료제 뉴론틴®¹



뉴론틴® 은 신경병증성 통증에 1차 치료제 중 하나로 권고되었습니다!¹

References

1. Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol.* 2015 Feb;14(2): 162-73.
2. 뉴론틴® 정 제품설명서 개정년월일 2024.05.13 3. 뉴론틴® 캡슐 제품 설명서 개정년월일 2024.09.21

[수입자 / 판매자]  비아트리스 코리아(주)

[04527] 서울특별시 중구 세종대로 14, 비동 15층 (남대문로 5가, 그랜드센트럴)
제품 의학정보 문의 Tel: 02-6411-6200 | E-mail: Viatrix-korea-MI@viatrix.com | Website: www.viatrix.co.kr

[판매자]  SK 케미칼

[13494] 경기도 성남시 분당구 판교로310 (삼평동)
제품 문의 Tel: 080-021-3131 | Website: www.skchemicals.com/ls



뉴론틴® 캡슐 제품 설명서




뉴론틴® 정 제품 설명서



KR-NEUR-2025-00005-06M# 2025

새롭고 튼튼한 뼈를 형성시켜주는 포스테오® 1-3

Bone Formation Marker, Bone Biopsy, Bone Mineral Density를 통해 Anabolic 효과가 확인된 골 형성 촉진제입니다. 1,2,4,5



Biopsy specimen images provided by Y.Jiang, UCSF.

※ 65세 여성의 뼈 생검 결과 치료 전과 포스테오 21개월 후의 Micro CT 이미지 (Micro CT image of iliac crest bone biopsies) 실제 환자 케이스는 일반 환자군에서의 임상적 결과와 다를 수 있습니다.



References 1, Forteo FDA Prescribing Information 2, Neer RM et al, Effect of parathyroid hormone [1-34] on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 2001 May 10;344(19):1434-41, 3, Kleerekoper M et al., Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength, J Bone Joint Surg Am, 2014 Jun 4;96(11):e90, 4, McClung MR et al., Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass, Arch Intern Med, 2005 Aug 8-22;165(15):1762-8, 5, Jiang Y et al., Recombinant human parathyroid hormone [1-34] [teriparatide] improves both cortical and cancellous bone structure, J Bone Miner Res, 2003 Nov;18(11):1932-41.

포스테오®주(테리파라타이드) [원료의 명칭 및 분량] 1mL 중 주성분: 테리파라타이드(유전자 재조합) (별칭 규격) 250µg (속주: E.coli K12 RQ228, 벡터: pHMM193) 보존제: 메타크레졸(유에스피) 3.0mg **[효능 · 효과]** - 폐경기 이후 여성 및 골질의 위험이 높은 남성에게 높은 여성 및 남성에게 있어서 지속적인 글루코코르티코이드 요법과 관련된 골다공증의 치료 **[용법 · 용량]** 권장용량은 1일 1회 이 약 20µg을 대퇴부 또는 복부에 피하주사한다. 환자들은 올바른 주사 방법에 대하여 교육을 받아야 한다. 환자에게 펜의 정확한 사용을 지도하기 위한 사용자 안내서(User manual)도 있다. 이 약의 사용기간은 최대 24개월이다. 한 환자의 일생에서 이 약의 24개월 과정을 반복해서는 안 된다. 만일 음식 섭취가 불충분한 경우에는, 환자들은 갈증과 비타민D 보조제를 추가적으로 섭취하여야 한다. 이 약의 치료가 끝난 후에는 환자들은 다른 골다공증 치료를 계속할 수 있다. **[사용상의 주의사항]** 1. 다음 환자에는 투여하지 말 것 - 테리파라타이드 또는 이 약의 부형제 성분에 대하여 과민반응 - 중증의 신장 기능 손상 - 일부 및 수유부 - 골격 악성종양 또는 골 전이가 있는 환자 - 기존의 고칼슘혈증 - 충분히 설명되지 않은 alkaline phosphatase의 상승 - 일차적인 골다공증 이외에 대사성 골질환 (부갑상선 기능 항진증 및 뼈의 Paget's disease 포함) - 이전에 골격에 방사선 치료를 한 경우 **[제조업체]** 전염성 위탁제조(제조외화): Eli Lilly Nederland B.V, Papendorpseweg 83, 3528 BJ Itrecht, Netherlands 일부공정위탁제조(제조자) [원료의약품] Boehringer-Ingelheim RCV GmbH & Co KG Dr.-Boehringer-Gasse 5-11 1121 Vienna, Austria, Lilly del Caribe 65th Infantry Rd., Km. 12,3(PRO5), Carolina, Puerto rico [한제의약품] Lilly France S.A.S Rue du Colonel Lilly, 67640 Fegershim, France 제품설명서 개정일자: 2021.01.25

※ 자세한 사항은 포스테오 제품설명서 전문을 참고해주시기 바랍니다.

WonderSeal™

Anti-adhesion Barrier Gel



일회용 의료기기

재멸균 금지

재사용 금지

CollaStat®

Bioactive Collagen Hemostat



뛰어난 지혈작용

콜라겐 단백질 입자의 팽창으로 인한 물리적 압박과 트롬빈의 혈액응고 작용의 시너지 효과로 신속하고 효과적인 지혈이 가능하여 수술시간이 단축됩니다.



최소한의 조작

다림티센의 독자적인 트롬빈 안정화 기술로 트롬빈 용액을 준비하는 과정 없이 주사기를 결합하여 혼합하는 최소한의 조작만으로 사용 준비가 가능합니다.



적용의 편리성

Flowable한 제품으로 불규칙한 표면이나 접근이 어려운 부위에 적용이 가능합니다.

CollaStat®

품목명: 흡수성 체내용 지혈용품(4등급)

허가번호: 제허 16-518호

사용목적: 외과적 수술시 체내조직을 지혈

사용기한: 제조일로부터 2년

저장방법: 1°C - 25°C

용량: 3ml / 6ml

dalim (주)다림양행

판매원: (주)다림양행

서울시 마포구 월드컵북로 52-1

TEL. 02-335-1657

dalim (주)다림티센

제조원: (주)다림티센

서울시 마포구 연희로31 연남빌딩 3층-5층

TEL. 02-3142-0646

Baxter

Tisseel
FIBRIN SEALANT

Floseal
HEMOSTATIC MATRIX

Hemopatch
HEMOSTAT

Ostene
BONE HEMOSTASIS
MATERIAL



국내 최초의 Pregabalin 25mg, 50mg¹

More than Pregabalin
카발린 캡슐
Pregabalin 25·50·75·150·300mg



Drug Information²

성분·함량

Pregabalin 25mg, 50mg, 75mg, 150mg, 300mg

효능·효과

1. 성인에서 말초와 중추 신경병증성 통증의 치료
2. 간질 : 성인에서 이차적 진전증상을 동반하거나 동반하지 않은 부분 발작의 보조제
3. 섬유근육통의 치료

용법·용량

이 약은 프레가발린으로서 1일 총 투여용량을 1일 2회로 나누어 음식물과 상관 없이 경구 투여한다. 이 약은 주로 신장으로 배설되므로, 신기능이 저하된 환자에 대해서는 용량이 조절되어야 한다. 1. 신경병증성 통증 1) 말초 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 3일 내지 7일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600 mg까지 증량할 수 있다. 2) 중추 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 1주일 후에 1일 300mg까지 증량할 수 있다. 추가로 1주일 후에 목표 1일 용량인 600mg까지 증량할 수 있다. 목표 1

일 용량에서 내약성을 나타내지 않을 경우 용량 감소를 고려할 수 있다. 2. 간질 (성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 일주일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 3. 섬유근육통: 이 약의 권장 용량은 1일 300mg~450mg 이다. 이 약은 시작 용량으로 75mg 씩 1일 2회(1일 150mg)를 투여하며, 유효성과 내약성에 근거하여 1주일 이내에 150mg씩 1일 2회(1일 300mg) 까지 증량할 수 있다. 1일 300mg의 용량에서 충분한 유효성을 경험하지 못한 환자의 경우에는 1주일 이내에 225mg씩 1일 2회(1일 450mg) 까지 증량할 수 있다. 1일 600mg의 용량에서도 임상 연구가 실시 되었으나, 이 용량에서의 부가적인 유효성이나 충분한 내약성에 대한 증거는 없다. 용량 의존적인 이상반응을 고려하면, 1일 450mg을 초과하는 용량 투여는 권장되지 않는다.

사용상의 주의사항

1. 경고 1) 자살충동과 자살행동 (1) 항간질약을 복용한 환자에서 자살충동 또는 자살행동을 보이는 위험성이 증가하므로 항간질약을 치료받은 환자는 자살충동 또는 자살행동, 우울증의 발현 또는 악화 및 기분과 행동의 비정상적 변화에 대하여 모니터링되어야 한다.(2) 항간질약을 처방받은 간질과 다른 많은 질병은

그 자체가 이환 및 사망, 치료기간 동안의 자살충동과 자살행동의 위험성증가와 관련된다. 따라서 처방자는 항간질약 처방시 환자의 치료기간 동안 자살충동 또는 자살행동과 치료될 질병간의 연관성 유무 및 이 약의 유효성을 함께 고려한다. 2. 다음 환자에는 투여하지 말 것 1) 프레가발린 또는 이 약의 성분에 과민한 환자 2) 이 약은 유당을 함유하고 있으므로, 갈락토오스 불내성 (galactose intolerance), Lapp 유당분해효소 결핍증 (Lapp lactase deficiency) 또는 포도당-갈락토오스 흡수 장애 (glucose-galactose malabsorption) 등의 유전적인 문제가 있는 환자에게는 투여하면 안 된다.

* 기타 자세한 사항은 제품설명서를 참고하십시오.

inno.N

에이치케이이노엔 주식회사

충청북도 청주시 흥덕구 오송읍 오송생명2로 239

서울 지사: 서울특별시 중구 을지로 100 파인에비뉴 6, 7, 8층

http://www.inno-n.com | Tel. 080-700-8802



Medtronic

Infuse™ Bone Graft

Trusted. Proven. Predictable.



The Premium Product for Autograft Replacement with high osteoinductivity demonstrated safety and effectiveness in multiple clinical trials.



MFDS Official Indication (수허21-274호):

Single Level OLIF

(Oblique Lateral Interbody Fusion)

- Clydesdale™ Spinal System
- Pivox™ Oblique Lateral Spinal System

Single Level ALIF

(Anterior Lumbar Interbody Fusion)

- Perimeter™ Interbody Fusion Device
- Divergence-L™ Interbody Fusion Device



이전에 없던 새로운 NSAID + 근이완제 복합제



에페신ACE 정

Eperisone 75mg + Aceclofenac 100mg

1st 발매 Eperisone + Aceclofenac 복합제 에페신ACE정

1st 제품 근이완제 1위 에페신SR정

1st 제약사 근이완제 전체 1위 명문제약

cf. UBIST data 2022년 처방조제약 기준

DRUG INFORMATION

【제품명】 에페신에이스정 **【보험코드】** 649808060 **【보험약가】** 378원/정 **【성분·함량】** 1정 중, 에페리손염산염 75mg, 아세클로페낙 100mg **【성상】** 흰색 내지 거의 흰색의 원형 서방성 필름코팅정 **【효능·효과】** 근골격계 근육 연축 증상을 동반한 급성 요통 환자의 통증 완화 **【용법·용량】** ○ 성인 : 1일 2회, 1회 1정 식후 경구 투여한다. 이 약은 분쇄하거나 분할 또는 씹지 않고 전체를 복용한다. 이상반응을 최소화하기 위하여 최단 기간 동안 투여해야 한다. ○ 간장애 환자 : 투여용량 감량이 필요한 간장애 환자 초기 치료 시, 이 약의 투여가 권장되지 않는다. ○ 고령자 : 고령자 중 투여용량의 감량이 필요한 경우에는, 이 약의 투여가 권장되지 않는다. **【저장방법】** 기밀용기, 실온보관(1~30℃) **【사용기간】** 제조일로부터 36개월 **【포장단위】** 30정/병, 100정/병 * 자세한 사항은 제품설명서를 참조하세요.


치료제의 명가 -
 **명문제약(주)**

A NEW MECHANISM FOR MULTIMODAL PAIN MANAGEMENT

PAIN CONTROL WITH LESS OPIOID RELIANCE

12시간 통증 강도 차이의 합 (SPID 12)

35% 개선




오나프라® 주 투여군은 위약군 대비 12시간 통증 강도 차이의 합(SPID 12)에서 유의한 개선 효과를 보였습니다.

SPID (Sum of Pain Intensity Difference)

수술 후 2-12시간 Opioid 사용량

37% 감소



오나프라® 주 투여군은 위약군 대비 수술 후 2~12시간 동안 PCA 및 구제 진통제의 OPIOID 사용량을 유의하게 감소시켰습니다.

PCA (Patient-controlled analgesia)



Study objective: VVZ-149 is a small molecule that inhibits the glycine transporter type 2 and the serotonin receptor 5-hydroxytryptamine 2 A. In this Phase 3 study, we investigated the efficacy and safety of VVZ-149 as a single-use injectable analgesic for treating moderate to severe postoperative pain after laparoscopic colectomy. Design: Randomized, parallel group, double-blind, Phase 3 clinical trial (Trial no. NCT05764525). Setting: 5 tertiary referral centers in South Korea. Patients: 284 patients undergoing laparoscopic colectomy. Interventions: A continuous 10-h intravenous infusion of VVZ-149 (n = 141) or placebo (n = 143) administered after emergence from anesthesia. Measurements: Pain intensity was assessed using a numeric rating scale (NRS) from the start of infusion for 48 h. The primary efficacy measure was the Sum of Pain Intensity Difference (SPID) for the first 12 h after the start of drug infusion. Other efficacy measures included SPID at other time points, opioid consumption via on-demand patient-controlled analgesia (PCA) and rescue medication, and proportion of patients who did not require rescue opioids for 48 h post-dose.

unafra® Inj.
Opiranserin HCl 1000mg/100mL

[제품명] 오나프라® 주 / UNAFRA® inj. [주성분] 오피란세린염산염 1,000mg/100mL [효능·효과] 성인에서 수술 후 중등도에서 중증의 급성통증 조절을 위한 단기요법 [용법·용량] 이 약은 성인에서 수술 후 중등도에서 중증의 급성통증 조절을 위해 단회투여한다. 필요시, 수술 후 초기 통증 조절을 위해 통증자가조절법(patient-controlled analgesia; PCA)을 사용할 수 있다. 부하용량으로 160 mg을 30분간 정맥 점적투여하고, 유지용량으로 840 mg을 9시간 30분간 정맥 점적투여한다. 최대 1,000 mg을 초과해서는 안 된다. 이 약 1,000 mg에 해당하는 100 mL을 생리식염주사액 400 mL에 희석하여 총 500 mL을 10시간 동안 말초 정맥을 통해 점적투여한다. 조제된 정맥주입용액은 48시간 이내에 사용해야 한다. 경막외 및 척수투여는 하지 않으며, 재투여에 대한 안전성, 유효성은 평가된 바 없다. [사용상의 주의사항] 1. 금기 1) 이 약에 과민반응이 있는 환자 2) 불안정 협심증, 울혈성 심부전 환자, 심전도 측정치 중 QRS > 200msec 이거나 QTcF > 450msec(남성) 또는 QTcF > 470msec(여성)인 자 3) 중등도-중증의 신장에 환자 4) 중등도-중증의 간장애 환자 5) 18세 미만 소아 환자 6) 임부 및 수유부 7) PR 또는 QRS 간격을 증가시킨다고 알려진 약물을 투여한 환자 8) 강력한 CYP3A4 억제제를 투여한 환자 2. 이상반응을 복강경 대장절제술 환자를 대상으로 진행된 3상 임상시험(K301시험)에서 총 284명(이 약 투여군 141명, 위약군 143명)을 대상으로 이 약 1,000 mg을 10시간 동안 정맥 점적투여하여 안전성을 평가한 결과, 이 약 1,000 mg을 투여받은 환자 중 101명(71.6%), 위약을 투여받은 환자 중 98명(68.5%)에서 이상반응이 확인되었다. 대부분의 이상반응은 경증에서 중등도였다. 가장 흔하게 보고된 이상반응은 구역(34.0%), 수술 후 열(31.9%), 구토(13.5%)였다. 이 약을 투여받은 수술 후 통증 환자(이 약 투여군 468명, 위약군 409명) 대상 안전성 분석 결과, 이 약을 투여받은 환자 중 364명(77.8%) 위약을 투여받은 환자 중 290명(70.9%)에서 이상반응이 확인되었다. 가장 흔하게 보고된 이상반응은 구역(45.1%), 구토(15.6%), 두통(14.5%), 수술 후 열(11.5%), 어지러움(10.5%), 졸림(6.0%)이었다. 흔하지는 않지만 심전도 PR 연장(1.3%)과 QRS 복합 연장(0.9%)이 보고되었다. [개정년월일] 2024년 12월 12일 *본 정보는 요약된 일부의 정보입니다. 따라서 자세한 사항은 제품 설명서 전문을 참고하시거나 의약품전지나라(nedrug.mfds.go.kr)의 의약품 정보를 참고하십시오.

[Reference] Lee, Ho-Jin, et al. "Reduction of Postoperative Pain and Opioid Consumption by VVZ-149, First-in-Class Analgesic Molecule: A Confirmatory Phase 3 Trial of Laparoscopic Colectomy." *Journal of Clinical Anesthesia* 101 (2025): 111729

[공동판매원]



서울사무소 : 서울시 송파구 올림픽로 35길 123 영군타워 7층
공정 : 경기도 화성시 향남읍 제막공단2길 34-40
Tel. 02-3434-7600 | www.vivozonpharm.com

[공동판매원]



한국다이하이지산교주식회사
Daiichi-Sankyo

한국다이하이지산교 주식회사
주소 : 서울시 중구 을지로 5길 26 미래셋 센터빌 빌딩 동관 15층
Tel. 02-3453-3330 | www.daiichisanjyoo.co.kr

Osteoporosis treatment proven for its efficacy and safety through a clinical trial including **Korean participants**¹⁾

Obodence[®] Pre-filled syringe (Denosumab) **60 mg / 1 mL**



- ✔ Treatment of osteoporosis in postmenopausal women²⁾
- ✔ Treatment to increase BMD in men with osteoporosis²⁾
- ✔ Treatment of glucocorticoid-induced osteoporosis²⁾
- ✔ Treatment of bone loss in patients with non-metastatic prostate cancer receiving androgen deprivation therapy²⁾
- ✔ Treatment of bone loss in women with breast cancer receiving adjuvant aromatase inhibitor therapy²⁾

※ This information is approved by the MFDS (KR). For information approved by the FDA and EMA, please refer to the respective country's product label.

Product Information²⁾

Dosage Forms and Strengths	Injection: 60 mg/mL solution in single-dose prefilled syringe	Dosage and Administration	Administer 60 mg every 6 months as a SC injection	Packaging Information	1 X prefilled syringe(1 mL)/box
Duration of Use	36 months from the date of manufacture	Storage Conditions	Refrigerate at 2-8°C in a hermetic container. Protect from light. Do not freeze.		

BMD: bone mineral density **SC:** subcutaneous

Ref 1) Langdahl B, et al. *J Clin Endocrinol Metab.* 2024 Sep;dgae611. **2)** The Ministry of Food and Drug Safety (KR). Obodence 60mg solution for injection in pre-filled syringe [product approval information]. Cheongju: MFDS; 2023 [cited 2025 Apr 16].

[Dosage forms] Injection: clear, colorless to slightly yellow solution in a single-dose prefilled syringe **[Ingredients and amounts]** Injection: 60 mg/mL solution in single-dose prefilled syringe, Active ingredient: denosumab, Inactive ingredients: histidine, histidine hydrochloride monohydrate, polysorbate 20, sorbitol, and water for injections **[Indications and usage]** **1.** Treatment of osteoporosis in postmenopausal women **2.** Treatment to increase BMD in men with osteoporosis **3.** Treatment of glucocorticoid-induced osteoporosis **4.** Treatment of bone loss in patients with non-metastatic prostate cancer receiving androgen deprivation therapy **5.** Treatment of bone loss in women with breast cancer receiving adjuvant aromatase inhibitor therapy **[Dosage and administration]** The recommended dose of Obodence is 60 mg administered as a single subcutaneous injection once every 6 months. Administer Obodence via subcutaneous injection in the upper arm, the upper thigh, or the abdomen. All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily. If a dose of Obodence is missed, administer the injection as soon as the patient is available. Thereafter, schedule injections every 6 months from the date of the last injection. **[Precautions for use]** Obodence(denosumab) is biosimilar to Prolia (denosumab),(omitted)

[Packaging information] 1 X prefilled syringe(1mL)/box **[Storage Conditions]** Refrigerate at 2-8°C in a hermetic container. Protect from light. Do not freeze. **[Duration of use]** Do not use Obodence after the expiry date printed on the label.

[Importer] Samsung Bioepis Co., Ltd., 76, Songdogoyouk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea **[Legal manufacturer]** Samsung Bioepis Co., Ltd., 76, Songdogoyouk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea

※ For detailed drug information, please refer to the Ministry of Food and Drug Safety's Drug Integrated Information System (<https://hedrug.mfds.go.kr> → 'Drug Information' → 'Drug and Cosmetic Product Information' → 'Drug Information Search').

※ Any changes made after the date of this document's creation (revision) can be found on the Ministry of Food and Drug Safety's Drug Integrated Information System (<https://hedrug.mfds.go.kr>).